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ABSTRACT:  Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are 29 
generated from aerobic metabolism, as a result of accidental electron leakage as well as regulated 30 
enzymatic processes. Because ROS/RNS can induce oxidative injury and act in redox signaling, 31 
enzymes metabolizing them will inherently promote either health or disease, depending upon the 32 
physiological context. It is thus misleading to consider conventionally-called antioxidant 33 
enzymes to be largely, if not exclusively, health-protective. Because such notion is nonetheless 34 
common, we herein attempt to rationalize why this simplistic view should be avoided. First we 35 
give an updated summary of physiological phenotypes triggered in mouse models of 36 
overexpression or knockout of major antioxidant enzymes. Subsequently, we focus on a series of 37 
striking cases that demonstrate “paradoxical” outcomes, i.e. increased fitness upon deletion of 38 
antioxidant enzymes or disease triggered by their overexpression. We elaborate mechanisms by 39 
which these phenotypes are mediated via chemical, biological, and metabolic interactions of the 40 
antioxidant enzymes with their substrates, downstream events and cellular context. Furthermore,  41 
we propose novel treatments of antioxidant enzymes-related human diseases by deliberate 42 
targeting dual roles of the pertaining enzymes, and outlined potential of “antioxidant” nutrients 43 
and phytochemicals, via regulating the expression or function of antioxidant enzymes, in 44 
preventing, treating, or aggravating chronic diseases. We conclude that “paradoxical” roles of 45 
antioxidant enzymes in physiology, health, and disease derive from sophisticated molecular 46 
mechanisms of redox biology and metabolic homeostasis. Simply viewing antioxidant enzymes 47 
always beneficial is not only conceptually misleading but also clinically hazardous if such 48 
notions underpin medical treatment protocols based upon modulation of redox pathways.   49 
Key Words: Antioxidant Enzyme, Knockout, Overexpression, Oxidative Stress, Redox 50 
Signaling 51 
52 
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I. INTRODUCTION 53 
 54 
Antioxidant enzymes are often discussed in scientific research and daily life as key players of 55 
metabolism that promote healthy cells, tissues and organisms. The term best relates to enzymes 56 
that lower the levels of reactive oxygen species (ROS) and reactive nitrogen species (RNS), or 57 
counteract their downstream cellular effects of excessive oxidation. ROS and RNS are produced 58 
from aerobic biogenesis or by oxidative enzymes, and being chemically reactive they have the 59 
capacity to damage cellular components. Nature has evolved three layers of antioxidant defense 60 
in the body. Small molecular antioxidants, including uric acid, glutathione (GSH), and vitamins 61 
C and E, offer the first line of defense to scavenge ROS/RNS directly and thus prevent or delay 62 
the initiation of various oxidative stresses. Damage-removing or repairing enzymes function as 63 
the last defense to regenerate biomolecules damaged from oxidative injury. Between these two 64 
layers, antioxidant enzymes serve as an intermediate defense to detoxify ROS/RNS into less 65 
reactive species. Superoxide (O2
-
) and hydrogen peroxide (H2O2) represent arguably the best-66 
known and most-produced ROS, with the former scavenged by superoxide dismutases (SOD)
1
 67 
and the latter by catalase (CAT), glutathione peroxidases (GPX), and peroxiredoxins (PRX). 68 
Thioredoxin reductases (TrxR) are in addition required to maintain functions of thioredoxins 69 
(Trx), PRX, methionine sulfoxide reductases (Msr) and many other redox-regulatory 70 
enzymes/proteins by regenerating protein thiols (411) in parallel with glutaredoxins (Grx) 71 
                                                 
1
Genes and proteins are in this article typically named according to HUGO 
(http://www.genenames.org) and MGI 
(http://www.informatics.jax.org/mgihome/nomen/gene.shtml) guidelines for human and mouse, 
respectively, unless other names or abbreviations are by convention more prevalent in the 
literature. In some cases mice have been studied with overexpression from human transgenes, 
which may be somewhat confusing in terms of nomenclature. We believe, however, that the 
references given in the Tables of this review article will serve as useful reference material for 
any reader interested in the exact gene constructs that are being discussed. 
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utilizing GSH to catalyze reduction of protein disulfide substrates (180, 395), These ROS-72 
metabolizing and reductive enzymes, which also play important roles in RNS homeostasis, are 73 
widely considered to be the major antioxidant enzymes and are the focus of this review article. 74 
 75 
During the past two decades, developments of antioxidant enzyme gene knockout and 76 
overexpression mouse models (Table 1) have enabled us to not only verify “anticipated” 77 
metabolic health-promoting functions of these enzymes, but also to reveal often neglected 78 
“paradoxical” roles of antioxidant enzymes triggering metabolic disorders. It has indeed become 79 
clear that many antioxidant enzymes are more than just protective ROS/RNS scavengers. They 80 
regulate many redox signaling pathways and may also exhibit pro-oxidant functions or functions 81 
independent of their redox activities.  82 
 83 
A number of chronic diseases are associated with genetic or metabolic alterations of antioxidant 84 
enzymes, displaying either lower or increased activities, depending upon the actual enzyme and 85 
disease. Meanwhile, certain “antioxidant” nutrients and phytochemicals are able to regulate 86 
antioxidant enzyme expressions or functions with health implications. Therefore it is important 87 
to have a better understanding of the “paradoxical” functions of antioxidant enzymes in 88 
physiology, which explain how their overexpression can promote disease or their deletion can be 89 
health-promoting. It is our goal that this review will help to support awareness of the involved 90 
molecular mechanisms and thus be useful in advancing a more balanced view of antioxidant 91 
enzyme and redox biology in medicine.  92 
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II. IMPACTS OF KNOCKOUT AND OVEREXPRESSION  93 
 94 
Superoxide- and H2O2-metabolizing enzymes, including SOD, catalase, GPX and PRX, are 95 
generally considered to be the primary antioxidant enzyme defense system in the body. However, 96 
the only antioxidant enzymes that have thus far been found to be essential for mouse embryonic 97 
development and thus lethal when genetically deleted are GPX4 (68, 293, 725), the two genes for 98 
cytosolic and mitochondrial TrxR, Txnrd1 (51, 305) and Txnrd2 (123), their cognate substrate 99 
Trxs, Txn1 (438) and Txn2 (490), as well as an essential gene for synthesis of GSH (604). 100 
Deletion of the Trsp1 (encoding selenocysteine tRNA (tRNA
[Ser]Sec
) gene that is required for 101 
synthesis of all selenoproteins is also embryonically lethal (54). Genetic deletion of several other 102 
antioxidant enzymes trigger strong phenotypes even if not being embryonically lethal, while 103 
certain antioxidant enzymes seem to have an impact only under severe oxidative stress or in 104 
specific tissues.  105 
 106 
While the SOD family represents the only enzymes able to scavenge O2
-
, catalyzing its 107 
disproportionation into O2 and H2O2, multiple classes of enzymes detoxify H2O2 or organic 108 
peroxides. Catalases scavenge H2O2 by catalyzing its disproportionation into O2 and H2O. Some 109 
selenoproteins and thiol peroxidase such as GPXs, and PRXs, catalyze the 2-electron reduction 110 
of peroxides to form water using reducing equivalents from GSH or Trx, respectively. The 111 
functions of GPXs and PRXs are thus intimately coupled to those of glutathione reductase (GR) 112 
and TrxR, enzymes that catalyze the reduction of oxidized GSH (GSSG) and Trx, respectively, 113 
using reducing equivalents from NADPH (185, 411). In addition, exciting progress has been 114 
made in understanding functions of Se-dependent methionine-R-sulfoxide reductase 1 (MsrB1) 115 
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that is a Trx-dependent enzyme. Much progress has also been made in the understanding of 116 
selenoprotein P (Sepp1) and Trsp gene that are both crucial entities for Se homeostasis and 117 
functions of all selenoproteins. Because prior reviews have discussed many of the detailed 118 
phenotypes in mice with knockout or overexpression of different antioxidant enzymes (62, 69, 119 
71, 80, 122, 337, 361, 377, 499), we will provide herein only an updated synopsis on the same 120 
subject, as a basis for the subsequent chapter focusing on their “paradoxical” roles.    121 
 122 
A. Superoxide Dismutase Family 123 
 124 
1. SOD1 125 
 126 
 Knockout of Sod1 does not cause embryonic lethality in mice, but results in impairment of the 127 
reproduction function of both males and females. Whereas the males produce sperm with 128 
decreased motility and fertilizing ability (207, 658), the females display a marked increase in 129 
postimplantation embryonic lethality (264) associated with elevated two-cell arrest or cell death 130 
(334). The Sod1
-/-
 mice develop anemia (299) and type 1-like diabetes (684). These mice also 131 
show a reduced lifespan, a high incidence of hepatocarcinogenesis in late life, and oxidative 132 
damage-accelerated spontaneous mutations in liver and kidney (73, 167). Although mice 133 
overexpressing SOD1 are apparently normal with a reduced mutation frequency in cerebellum 134 
(357), these animals exhibit certain abnormalities found in patients with Down's syndrome (23, 135 
24, 524, 580).   136 
 137 
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Knockout and overexpression of SOD1/Sod1 exert negative and positive impacts, respectively, 138 
on mouse susceptibility or resistance to neurodegenerative disorders, cerebral and myocardial 139 
injuries, diabetic syndrome, and tissue intoxications and dysfunctions (Table 2). However, most, 140 
if not all, of the reported “mechanisms” are associations between phenotypes and genetic 141 
manipulations, without genuine knowledge of the exact molecular mechanisms that lead to the 142 
observed phenotypes. Importantly, the association of SOD1 mutations with familial amyotrophic 143 
lateral sclerosis (ALS) does not seem to be due to effects on enzyme activity but rather an 144 
increased propensity for protein aggregation (203, 373, 474, 491). Impacts of Sod1 knockout or 145 
SOD1 overexpression in mice on neurodegenerative disorders may be related to effects on Aβ 146 
oligomerization (477), dopaminergic neurodegeneration (746), lipid peroxidation (536, 647), and 147 
protein nitration (294). In cell studies, altering the enzyme affects dopamine autoxidation and 148 
changes of GSH (242), and neuroinflammation driven by activation of nuclear factor-κB (NFκB), 149 
release of nitric oxide (NO), and proinflammatory cytokines (153).  150 
 151 
Overexpression of SOD1 protects against various brain and neurological injuries by: 1) 152 
attenuating the mitochondria-mediated apoptosis pathway (e.g., release of cytochrome c and 153 
nuclear translocation of endonuclease G) (624, 737); 2) suppressing the induced expression of 154 
matrix metalloproteinases (467); and 3) activating Akt/glycogen synthase kinase 3β (GSK-3β) 155 
survival signaling (169, 313).  Meanwhile, the protection against cerebral ischemia is conferred 156 
in part by up-regulating Akt and down-regulating p38 mitogen-activated protein kinase (MAPK), 157 
and NFκB (100).  In contrast, Sod1 knockout potentiates mice to ischemic injuries by activating 158 
NFκB (100), and lung dysfunction by increasing nuclear factor of activated T-cells (NFAT) and 159 
NFATc3 activities (546). Sod1 knockout can also trigger kidney dysfunction by enhancing the 160 
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oxidative stress-induced phosphorylation and the conversion of iron responsive protein-1 (IRP1) 161 
to the iron responsive element (IRE)-binding form, which may accelerate the reabsorption of iron 162 
by renal tubular cells (734). Inhibition of matrix protein synthesis induced by high glucose (129) 163 
and the NO-O2
-
 interaction (148) contributes to the protection of SOD1 overexpression against 164 
diabetic nephrophathy. Seemingly, several, if not all, of these SOD1-altered phenotypes are 165 
associated with specific redox signaling effects, rather than a direct free radical scavenging.   166 
 167 
2. SOD2  168 
 169 
Sod2
-/-
 mice, unlike Sod1
-/-
 mice, develop cardiomyopathy and neonatal or perinatal lethality, 170 
despite variations in postnatal survival time and neuronal injury (370, 392). Thus, the reported 171 
phenotypes of Sod2 knockout are mostly derived from haplodeficiency or tissue-specific 172 
inactivation of the gene. While Sod1
-/-
 female mice become infertile (264), ovaries from 173 
postnatal Sod2
-/-
 mice undergo normal folliculogenesis and can produce viable offspring when 174 
transplanted to the bursa of wild-type hosts, suggesting the enzyme dispensable for the ovarian 175 
function (443). Interestingly, strain-dependent overexpression of SOD2 is associated with growth 176 
retardation and decreased fertility in transgenic mice (542) (Table 3). Although the Sod2
+/-
 mice 177 
are viable and no more sensitive to hyperoxia (304), their mitochondria show decreased 178 
respiratory capability and elevated induction of the permeability transition (697).   179 
 180 
Likewise, knockout and overexpression of Sod2/SOD2 produces negative and positive impacts, 181 
respectively, on mouse susceptibility or resistance to a number of acute or chronic disorders 182 
(Table 3). Such opposite effects of the enzyme on neurodegenerative disorders are related to 183 
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regulating mitochondrial ROS generation and function, shifting the amyloidogenic Aβ 184 
composition (435), slowing amyloid deposition and memory deficit (164, 435), and modulating 185 
dopaminergic neurodegeneration (11, 342).  Similarly, the effects on ischemic cerebral injuries 186 
are through regulations of blood-brain barrier, matrix metalloproteinases (MMPs), and 187 
inflammatory responses (425). Knockout of Sod2 aggravates cellular senescence and aging (653, 188 
675), though overexpression of Sod2/SOD2 fails to extend life span despite preserving age-189 
associated loss of mitochondrial function (308, 374).  Overexpression of the enzyme protects 190 
against diabetes and complication through improved mitochondrial respiration and integrity and 191 
decreased iNOS and NO production (50, 226, 273, 351, 408, 597). Interestingly, old Sod2
+/-
192 
Gpx1
-/-
 mice have an elevated incidence of neoplasms (750), suggesting that knockout of 193 
multiple antioxidant enzymes can have synergistic effects on carcinogenesis.  194 
   195 
3. SOD3  196 
 197 
Knockout of Sod3, unlike Sod1 or Sod2, does not affect mouse development and lifespan or 198 
further worsen the shortened lifespan of Sod1
-/-
 mice, suggesting limited overlapping roles 199 
between these enzymes (81, 593). Respective protective and detrimental outcomes from 200 
overexpression and knockout of SOD3/Sod3 are seen in brain, heart and vascular system, kidney, 201 
lung and immune system, as well as in ischemic injuries and carcinogenesis (Table 4).  202 
   203 
This extracellular SOD isoenzyme plays a pivotal role in protecting against a number of lung 204 
disorders including oxidative injury, inflammation, and fibrosis (7, 8, 81, 189, 212, 248, 318, 492, 205 
528, 539, 625, 672). Different from those lacking Sod1, Sod2, or catalase, the Sod3
-/-
 mice are 206 
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susceptible to hyperoxia and induced oxidative injury (81). Protective roles of the enzyme in 207 
pulmonary fibrosis have been thoroughly reviewed (205), and its unique importance in 208 
pulmonary function is attributed to its extracellular localization, the pathological importance of 209 
extracellular matrix expression, and cytokine release elicited by extracellular ROS. Involved 210 
signaling events include modulation of transforming growth factor beta (TGF-β) and early 211 
growth response protein 1 (Egr-1) expression (672), preserving angiogenesis (528), and 212 
maintaining NO bioavailability and subsequent modulating cGMP and NFκB activity (7). The 213 
unique protection by SOD3 against lung oxidative insults offers potential of administrating of the 214 
enzyme to relieve pulmonary disorders (205). Moreover, the distribution of SOD3, rather than 215 
the total SOD activity, in the extracellular space is crucial for protecting heart against the 216 
pressure overload as this insult renders the Sod3
-/-
 mice elevated myocardial O2
-
 production and 217 
nitrotyrosine formation, increases of ventricular collagen I & III, MMP-2 and -9, and decreases 218 
in ratio of GSH/GSSG (glutathione disulfide) (414). Knockout of Sod3 renders mice susceptible 219 
to the collagen-induced arthritis (570), while overexpression of SOD3 in mouse synovial tissue 220 
attenuates the inflammatory arthritis (736), via opposite modulations of the production of the 221 
pro-inflammatory cytokines such as IL-1β and TNFα, and MMPs. Knockout of Sod3 also 222 
impairs renal-vascular function, in part by decreasing Akt and eNOS phosphorylation and heme 223 
oxygenase 1 activity (326). 224 
 225 
B.  Catalase 226 
 227 
Catalase is ubiquitously expressed, and is predominantly located in peroxisomes of all types of 228 
mammalian cells with the exception of erythrocytes (669) and human vascular cells (607). A 229 
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certain activity of catalase is also detected in mitochondria of rat heart (541). In humans, 230 
acatalesemia is a comparatively common genetic disease with near-total lack of catalase, which 231 
is typically considered to be asymptomatic but may be associated with increased risk of a 232 
number of diseases  (224). Cat
-/-
 mice show normal development and fertility (268), and are not 233 
more susceptible to the hyperoxia-induced lung injury than the wild-type controls. 234 
Overexpression of catalase in mitochondria prolongs the lifespan of mice and attenuates age-235 
associated pathological changes (137, 504, 584, 654). The overall outcomes of Cat knockout are 236 
rather limited, especially in comparison with those associated with Sod. This may in part be due 237 
to the fact that GPX and PRX (90, 184) play major roles in removing H2O2 at relatively low 238 
concentrations in the cells, whereas the contribution of catalase increases when intracellular 239 
H2O2 is high (428). 240 
 241 
In contrast, promotion of health by CAT/Cat overexpression has been shown in many tissues and 242 
conditions (Table 5). Overexpression of CAT protects against cardiovascular injuries or 243 
dysfunction (424, 723, 724), which is particularly relevant due to the lack of the enzyme activity 244 
in the human vascular smooth muscle and endothelial cells (607). Aortas from apolipoprotein E 245 
knockout mice overexpressing CAT show smaller and relatively early stages of atherosclerotic 246 
lesions compared with the control (722).  Cardiac-specific overexpression of rat Cat attenuates 247 
the paraquat-induced myocardial geometric and contractile alteration by alleviating JNK-248 
mediated endoplasmic reticulum stress (208), prolongs lifespan, and suppresses aging-induced 249 
cardiomyocyte contractile dysfunction and protein damage (712). Also, this specific 250 
overexpression of rat Cat rescues the anthrax lethal toxin- or lipopolysaccharide-induced cardiac 251 
contractile dysfunction by alleviating oxidative stress, autophagy, and mitochondrial injury (317, 252 
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660). The elevated catalase antagonizes the alcohol dehydrogenase-associated contractile 253 
depression after acute ethanol exposure in murine myocytes, partially through improving 254 
intracellular Ca
2+
 handling and ablation of alcohol dehydrogenase-amplified JNK activation and 255 
Erk de-activation (748, 749). Comparatively, the endothelium specific overexpression of CAT 256 
shows a weak protection against myocardial or vascular ischemia/reperfusion injury, despite 257 
preserving the responsiveness of the heart to adrenergic stimulation (704). Knockout of Cat 258 
accelerates diabetic renal injury through upregulation of TGF-β and collagen secretion (289), 259 
whereas overexpression of Cat protects against the pathogenesis via attenuation of 260 
angiotensinogen and Bax function and normalized expression of angiotensin converting enzyme 261 
2 (ACE-2) (58, 603).  262 
 263 
C. Glutathione Peroxidase Family   264 
 265 
GPX enzymes utilize reducing equivalents from GSH to reduce peroxides (60, 94, 185). Eight 266 
isoforms of GPX are known, of which five are selenoproteins (GPX1-4 and GPX6). The three 267 
selenium-independent GPX enzymes rely upon thiol rather than selenol chemistry. Among the 268 
GPX enzymes, GPX1 is the most abundant and ubiquitous isoform. GPX6 is found as a 269 
selenoprotein only in humans, while the orthologous Gpx6 has a catalytic cysteine (Cys) in mice 270 
and several other species (353). Several recent reviews have summarized physiological roles of 271 
GPX enzymes in relation to other selenoproteins (61, 360, 361, 554). Our discussion herein 272 
mainly summarizes the key findings from genetic mouse models. 273 
 274 
1. GPX1 275 
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 276 
Gpx1 is not essential for survival or reproduction, despite its protection against cataract and 277 
slight growth retardation (110, 141, 172, 265). Knockout of Gpx1 sensitizes mice to pro-oxidant-278 
induced oxidative injuries, whereas overexpression of the enzyme confers extra protection 279 
against such injuries in various tissues (Table 6). The elevated susceptibility of the Gpx1
-/-
 mice 280 
to various acute oxidative injuries, including increased lethality induced by high doses of 281 
paraquat and diquat, relates to accelerated oxidation of NAD(P)H, proteins, and lipids (108, 111, 282 
141, 195, 196). The importance and mechanism for Gpx1 protection depends upon the intensity 283 
of stress as well as antioxidant status of the challenged animals (108, 111, 141, 195, 196, 376) 284 
but high levels of dietary vitamin E do not replace protection of Gpx1 (113). It should also be 285 
noted that Gpx1 is one of the most Se-responsive selenoproteins, whereby low dietary Se intake 286 
rapidly lowers its expression in most tissues (631), suggesting that the Se status of the control 287 
mice will affect the comparative outcome of Gpx1 removal.  288 
 289 
Protections against disease conditions by GPX1 are illustrated by increased susceptibility of 290 
Gpx1
-/-
 mice and resistance of Gpx1 overexpressing mice to various oxidative insults, including 291 
ischemia/reperfusion and hypoxic ischemic injury in the brain, heart, and liver (128, 195, 341, 292 
397, 564, 595, 691, 732). Furthermore, Gpx1 protects against cardiomyopathy induced by 293 
coxsackievirus B3 through suppression of viral genome mutation (37), atherosclerosis in a pro-294 
diabetic ApoE
-/-
 mouse model (115, 384, 652), doxorubicin-induced and angiotensin II-mediated 295 
functional declines and cardiac hypertrophy (15, 206, 714, 733), defective blood flow and 296 
epithelial progenitor circulation in a model of ischemia-induced angiogenesis (202), diabetic 297 
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nephropathy in association with fibrosis and inflammation (115, 640, 641), and detrimental 298 
effects of cigarette smoking or influenza A infection in the lung (165, 726).  299 
 300 
Although the exact molecular mechanisms for involvement of Gpx1 in the above-described 301 
pathogeneses are largely unknown, the existing evidences point out ROS scavenging and redox 302 
signaling as the main modes of action. The Gpx1
-/-
 mouse brain shows elevated oxidative stress, 303 
caspase-3 cleavage, and 3-nitrotyrosine formation (128, 341). The decreased migration of 304 
endothelial progenitor cells in the Gpx1
-/- 
mice toward vascular endothelial growth factor (VEGF) 305 
and capability of these cells in promoting the formation of vascular network are indeed related to 306 
the elevated intracellular ROS levels (202). The protection of Gpx1 against diabetic nephropathy 307 
is associated with decreases of hydroperoxides, 8-isoprostane, nitrotyrosine, 4-hydroxynonenal, 308 
and proteins implicated in fibrosis and inflammation (115, 640, 641).  309 
 310 
2. GPX2 311 
 312 
GPX2 was first found in the gastrointestinal tissues (117). There are no Gpx2 transgenic mouse 313 
lines reported (Table 1). Like the Gpx1
-/-
 mice, Gpx2
-/-
 mice appear normal unless they are 314 
stressed by oxidative challenges (678). The Gpx1 expression is up-regulated in the colon and 315 
ileum of Gpx2
-/- 
mice (186), which may explain why they do not develop cancer spontaneously 316 
but develop squamous cell tumor when additional stress such as UV exposure is employed (678). 317 
Likewise, spontaneous polyps are developed in Gpx1
-/-
Gpx2
-/-
 mice, probably due to elevated 318 
intestinal lipid peroxidation with onset of inflammatory bowel disease (118, 174) (Table 7).  319 
Notably, nuclear factor (erythroid-derived 2) (NF-E2)-related factor (NRF2), a redox-sensing 320 
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transcription factor, may counteract oxidative injuries partially through up-regulation of Gpx2, at 321 
least in lung (613). Given its high expression in the gastrointestinal tract, GPX2 likely exerts 322 
antioxidant or anti-tumorigenic functions there, in association with GPX1 and NRF2. However, a 323 
basic question still remains as whether knockout of Gpx2 itself elevates intracellular H2O2 levels 324 
or affects NRF2 (352). 325 
 326 
3. GPX3 327 
 328 
GPX3 is mainly synthesized in proximal convoluted tubule cells of kidney (22). While the 329 
majority of renal GPX3 is secreted into plasma, some retains at the basement membranes to 330 
account for 20% of total selenium in kidneys (429, 505). Independent of its peroxidase activity, 331 
this enzyme transfers Se from the dams to the fetus (72), while Sepp1 instead of Gpx3 provides 332 
Se to neonates via the milk (257). Knockout of Gpx3 and overexpression of GPX3 in mice 333 
produce essentially opposite impacts on ROS-related events (Table 7). The Gpx3
-/-
 mice display 334 
cerebral infarctions, along with elevated oxidative stress, blood clot, the induction of P-selectin, 335 
and lowered plasma cGMP level (311) and colitis-associated carcinoma with increased 336 
inflammation in the colon (32). Overexpression of GPX3 renders mice resistant to 337 
acetaminophen (APAP) overdose (458) but leads to hyperthermia (457). Thus, some 338 
physiological effects of Gpx3/GPX3 modulation can be viewed as unexpected if the enzyme 339 
would solely have a role in extracellular H2O2 scavenging. It is thereby possible that it has yet 340 
unrecognized physiological functions that are not directly related to the extracellular enzymatic 341 
activity. 342 
 343 
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4. GPX4 344 
 345 
GPX4 has three isoforms in cytosol, mitochondria, and sperm nucleus, and enzymatically 346 
exhibits substrate preference toward phospholipid hydroperoxide (667). Interacting with 347 
guanine-rich sequencing-binding factor 1, GPX4 suppresses lipid peroxidation and apoptosis 348 
during embryogenesis (664).  Because the global knockout of Gpx4 renders embryonic lethality, 349 
tissue-specific and Gpx4 isoform-specific conditional knockout mice have been generated 350 
(Table 7). Collectively, increased levels of lipid peroxides by localized Gpx4 deficiency lead to: 351 
1) endothelial cell death and thrombus formation in a vitamin E-dependent manner (707); 2) 352 
12/15-lipoxygenase dependent apoptosis-inducing factor (AIF) translocation and neuronal 353 
apoptosis (590); 3) mitochondrial potential decline and infertility of spermatozoa (292); and 4) 354 
defective photoreceptor maturation (663). Recently it was shown that cell death by ferroptosis is 355 
triggered upon genetic removal of Gpx4 in either kidney (194) or T cells (441). Clearly, Gpx4 is 356 
important for protections against the detrimental effects of lipid peroxidation, but the enzyme 357 
also has an intriguing peroxidase-independent structural role in sperm maturation (667). 358 
 359 
Results from isoform-specific knockout of Gpx4 indicate that: 1) mitochondrial Gpx4 protects 360 
against apoptosis during hindbrain development (52); 2) mitochondrial Gpx4 suppresses protein 361 
thiol content, and is essential for male fertility (581); and 3) nuclear Gpx4 is essential for atrium 362 
formation (52), but indispensable for sperm maturation (581). Because the mitochondrial or 363 
nuclear Gpx4
-/-
 mice are viable, the cytosolic Gpx4 confers the embryonic lethality phenotype of 364 
the global Gpx4 knockout. Reciprocally, overexpression of GPX4/Gpx4 in the global Gpx4
-/-
 365 
mice, detected only in liver and heart, can rescue their embryonic lethality and attenuate the 366 
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induced mitochondrial potential declines (393, 548) (Table 7). Similarly, the mitochondrion-367 
specific Gpx4 overexpression maintains mitochondrial membrane potentials and protects against 368 
ischemia/reperfusion in the heart (136).  369 
 370 
D. Thioredoxin Reductase (TrxR) Family  371 
 372 
TrxRs are a family of NADPH-dependent selenoproteins, which play important roles as key 373 
propagators of the Trx system and thus several Trx-dependent enzymes, including PRX, Msr, 374 
ribonucleotide reductase (RNR), sulfiredoxin, and more (17, 122, 412, 423, 571). Three 375 
mammalian genes encode different TrxR isoforms, in mice being Txnrd1 encoding cytosolic 376 
TrxR1 (215, 325, 507), Txnrd2 encoding mitochondrial TrxR2 (also called TR3) (325, 454, 565, 377 
628) and Txnrd3 encoding thioredoxin glutathione reductase that is mainly expressed in 378 
spermatids of the testis and seems to be important for spermatogenesis (211, 623, 626, 627, 659). 379 
 380 
All Txnrd genes are transcribed in a complex manner, resulting in divergent forms of each 381 
isoenzyme that differ from each other mainly in their N-terminal domains (88, 95, 139, 211, 442, 382 
455, 507, 572, 573, 622, 629), potentially reflecting many levels of regulation. The phenotypes 383 
of mouse knockout models targeting the Txnrd1 and Txnrd2 genes are summarized in Table 8. 384 
No knockout models targeting Txnrd3 have yet been reported and overexpression of TrxR 385 
isoenzymes is difficult to obtain, due to their intricate expression patterns.  386 
 387 
1. TrxR1 388 
 389 
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The full Txnrd1
-/-
 knockout mice display early embryonic lethality, with one study reporting 390 
lethality between embryonic days 8.5 and 10.5 mainly due to decreased cellular proliferation 391 
(305), and the other study embryonic death before day 8.5 with a lack of formation of mesoderm 392 
(51). Differences in genetic targeting between these studies, one removing the last exon of the 393 
gene (305) and the other removing the first exon (51), may possibly help to explain the different 394 
phenotypes. Notably, the knockout in mice of the Trx1 gene encoding Trx1 (see below) that is 395 
the presumed main substrate of TrxR1, gives even earlier embryonic death than upon TrxR1 396 
removal (438). This suggests that functions of TrxR1 and Trx1 are not always directly linked in a 397 
physiological setting, which may be due to the fact that the GSH system can also keep Trx1 398 
reduced through Grx activities (162). It is, however, clear that TrxR1 is an essential enzyme for 399 
embryonic development in mice. 400 
 401 
Heart-specific Txnrd1
-/-
 mice are normal (305), as are mice with neuron-specific deletion of the 402 
enzyme (617). Interestingly, however, expression of the enzyme in glial cells is essential for 403 
normal development of the central nervous system (617). When deleted in either hepatocytes, 404 
mouse embryonic fibroblasts or B-cell lymphoma cells, the Nrf2-driven and mainly GSH-405 
dependent enzyme systems are typically strongly upregulated (302, 430, 520, 535, 634). In fact, 406 
it was found that the Nrf2 induction can be so strong upon TrxR1 deletion or inhibition that cells 407 
become even more resistant to certain events of oxidative challenge, than those having normal 408 
expression of TrxR1 (63, 405, 634) . These apparently paradoxical impacts on mouse 409 
susceptibility to stress upon TrxR1 removal will be further elaborated in the following chapters. 410 
 411 
2. TrxR2 412 
20 
 
 413 
Similarly to TrxR1, the mainly mitochondrial isoenzyme TrxR2 is essential for embryonic 414 
development. Interestingly, however, Txnrd2 knockout yields early embryonic death in a more 415 
tissue specific manner, presenting liver apoptosis, impaired hematopoiesis and insufficient heart 416 
development (123). Knockout of mitochondrial Trx2 that is presumed to be the main substrate of 417 
TrxR2, however, displays a more severe phenotype with massive widespread apoptosis and open 418 
anterior neural tube (490). This illustrates that the functions of TrxR2 are not always directly 419 
linked to those of Trx2, which is similar to the situation with Trx1 and TrxR1 (see above).   420 
 421 
There was a lack of overt phenotype when TrxR2 was conditionally knocked out in the nervous 422 
system (617) or in B- and T-cells (209), while its conditional knockout in heart produced obvious 423 
detrimental effects (123, 280). Recently, it was also shown that TrxR2 knockout in tumor cells 424 
prevented tumor growth because of a lack of hypoxia-inducing factor (HIF) function and JNK 425 
activation (254). These observations suggest that although most cells and tissues are dependent 426 
upon mitochondrial function, the physiological effects of genetic deletion of the mitochondrial 427 
TrxR2 enzyme are more specific than what would be explained by a generally impaired 428 
mitochondrial function in the whole organism.   429 
 430 
E. Additional Mouse Models for Knockouts of Selenoproteins 431 
 432 
 433 
Most, if not all, of the 24-25 selenoproteins in the mammalian proteomes (353) presumably have 434 
redox activity. Readers are referred to other recent reviews for a full survey of these proteins (84, 435 
124, 250, 322, 360). However, in the context of this article it is worth considering MsrB1, a 436 
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Trx1-dependent selenoenzyme, and Sepp1, as their physiological antioxidant roles have been 437 
studied using several genetic mouse models. Knockout of MsrB1 renders mice prone to lipid 438 
peroxidation and protein oxidation in tissues as well as defective actin polymerization in 439 
macrophages upon lipopolysaccharide challenge (190, 371) (Table 9). Neuronal protection by 440 
Sepp1, a predominant extracellular selenoprotein that delivers selenium from liver to other 441 
tissues and has peroxidase activity (576, 639), may be attributed to its selenium transport 442 
function, because deletion of its C-terminal region being rich in selenocysteine residues (amino 443 
acids 240-361) was sufficient to produce severe neurodegeneration in mice (258, 533, 583). 444 
Liver-specific expression of SEPP1 in Sepp1
-/-
 mice enhances their brain selenium content and 445 
rescues the neurological defects (559), further supporting the important role of this selenoprotein 446 
in the selenium transport.  447 
 448 
The redox activity of all selenoenzymes depends on the function of selenocysteine (Sec), which 449 
is cotranslationally incorporated at re-defined specific UGA codons in a process that requires 450 
tRNA
[Ser]Sec
, the transcriptional product of the Trsp gene.  Because Trsp
-/-
 mice are embryonically 451 
lethal (54), various conditional knockouts and variants of Trsp have been made to study roles and 452 
regulations of selenoproteins in specific tissues, resulting in several interesting phenotypes 453 
(Table 9). Intriguingly, knockout of Trsp in endothelial cells causes embryonic lethality and in 454 
muscle and liver induces postnatal death (76, 609). Global or conditional Trsp
-/-
 mice expressing 455 
wild-type or mutant Trsp transgene have also been generated (78, 591). These Trsp-altered 456 
mouse models help understand tissue-specific functions of selenium, and allow for recapitulation 457 
of mechanisms behind the classical selenium-deficiency syndrome, Kashin-Beck disease (161). 458 
A recent review (361) offers detailed discussion on the pleiotropic effects of Trsp targeting that 459 
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are likely to be derived from the combined effects of modulation of multiple selenoproteins at 460 
once. 461 
 462 
F.  Thioredoxin Family 463 
 464 
Trxs are small thiol-disulfide oxidoreductases with a Cys-Gly-Pro-Cys active site and are present 465 
in all living cells. The reduced forms with a dithiol motif in the active site catalyze disulfide 466 
reduction reactions, generating oxidized forms of Trx with a disulfide in the active site, which is 467 
again reduced by NADPH via TrxRs (276, 396).  The isoforms of Trx have a broad range of 468 
functions in mammalian cells (18), including to serve as electron donors for Prxs that are 469 
controllers of the intracellular redox state together with GSH (274), and being major protein S-470 
denitrosylases (91). The structure of Trxs comprises a central core of β-strands surrounded by α-471 
helices that defines the Trx-fold, now known to be present in a large number of proteins denoted 472 
the Trx superfamily of proteins. This includes Grx (395), glutathione S-transferases, GPXs, 473 
PRXs and proteins of the protein disulfide isomerases (PDI) family, which are all built from Trx 474 
domains (21). In the context of this review the main results of genetic mouse experiments for 475 
analyses of Trx1, Trx2, Grx1 and Grx2 are discussed as follows. 476 
 477 
1. Trx1 478 
 479 
Trx1 (encoded by Txn in mice) is ubiquitously expressed in the cytosol/nucleus, and has a large 480 
number of functions in cellular redox control and antioxidant defense (18). One of those 481 
functions is to provide reducing power to RNR that is essential for DNA synthesis. Because the 482 
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global knockout of Txn in mice induces early embryonic lethality (437), shortly after 483 
implantation with differentiation and morphogenesis defects, studies in adult mice were instead 484 
enabled using a dominant-negative mutant line in which the active site Cys-32 and Cys-35 485 
residues were altered to Ser (dnTrx-Tg) (140). These functionally Trx1-deficient mice display 486 
decreased Trx activity in the lung and are sensitive to ambient air at room temperature. These 487 
mice experience genotoxic stress, as evidenced by decreased activities of aconitase and NADH 488 
dehydrogenase, lower mitochondrial energy production, but increased levels of p53 and 489 
Gadd45α expression. These dnTrx-Tg mice are also manifested with increased levels of pro-490 
inflammatory cytokines (140), which are aggravated by exposure to hyperoxia. In contrast, 491 
overexpression of enzymatically active Trx1 in the lung (140) helps maintain redox balance and 492 
mitochondrial function with decreased inflammation. Mice overexpressing TXN have increased 493 
resistance to a range of oxidative stress insults (643). In addition, Trx1 has been shown to protect 494 
against joint destruction in a murine model of arthritis (657). Overexpression of the protein 495 
furthermore seems to promote fetal growth by reducing oxidative stress in the placenta (665), 496 
prevent diabetic embryopathy (314), and extend mainly the earlier part of the life span in mice 497 
with a prolonged youth phenotype (527). 498 
 499 
Trx1 is secreted from cells under inflammation and oxidative stress and is detectable in plasma 500 
(482). Of particular interest is that the extracellular Trx1 is taken up by cells and has been 501 
proposed as an effective antioxidant therapy (439, 483, 688). Its presumed antioxidant and anti-502 
apoptotic properties are tightly coupled with the reduced form of Trx1 binding to thioredoxin 503 
interacting protein 1(TXNIP) (475, 735) or apoptosis signaling kinase (ASK1) (290, 310). 504 
Extracellular Trx1 is however also found in plasma as a truncated form called Trx80, resulting 505 
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from α-secretase cleavage (213) and known to act as an inflammatory mediator (Th1) via effects 506 
on the immune system and monocytes (522). Both Trx1 and Trx80 seem to have a positive 507 
effects protecting from Alzheimer´s disease in the brain (213). Because Trx80 lacks redox 508 
activity together with TrxR1 (523) and since extracellular forms of these proteins are likely to 509 
remain oxidized, it is possible and even likely that some of their physiological roles are unrelated 510 
to redox activities.  511 
 512 
2. Trx2 513 
 514 
Trx2, with a mitochondrial leader sequence, is targeted to the mitochondria, where it plays a 515 
crucial role in controlling of ROS by acting as a reductant of Prx3 in concert with the GSH 516 
system and Grx2 (240, 744). Knockout of the Trx2 gene (490) induces embryonic lethality with 517 
massively increased apoptosis and exencephaly with open anterior neural tube. Cardiac specific 518 
deletion of Trx2 (283) produces spontaneous dilated cardiomyopathy at one month of age, with 519 
increased heart size, reduced ventricular wall thickness, and progressive decline in left 520 
ventricular contractile function result in mortality due to heart failure at young age. In 521 
cardiomyocyte-specific Trx2
-/-
 mice, mitochondrial function and ATP production are declined 522 
and ASK1-dependent apoptosis accelerated. Interestingly, humans with dilated cardiomyopathy 523 
have lowered Trx2 protein levels in heart tissue, suggesting that these mice could be a good 524 
model of the human disease (283). 525 
 526 
3. Grx1 527 
25 
 
Grx1 catalyzes GSH-disulfide oxidoreduction reactions (275), deglutathionylation of S-528 
gluthionylated proteins (277) and reduction of Trx1 by GSH when TrxR is inactivated (162). 529 
Surprisingly, knockout of Grx1 (267) results in only a mild phenotype without major effects on 530 
ischemia reperfusion injuries. However, knockout of the gene offers protection against 531 
inflammation or defective revascularization in diabetes (4, 270), which will be further elaborated 532 
in the following chapter. 533 
 534 
4. Grx2 535 
Grx2 is encoded by a gene resulting in splice variants including Grx2a located in mitochondria 536 
and Grx2c in the cytosol/nucleus. Knockout of Grx2 (710) induces early onset of age-dependent 537 
cataract in mice. Grx2 is also required to control mitochondrial function since knockout affects 538 
cardiac muscle (426, 427), giving rise to larger hearts and high blood pressure. 539 
 540 
G.  Peroxiredoxin Family 541 
 542 
The PRX enzymes are a family of abundantly present 20-30 kDa peroxidases (185, 562, 706). 543 
These homodimeric proteins fall into three varieties distinguished by their reaction mechanisms 544 
and the number of cysteine residues required for catalysis: typical 2-Cys (in mammals PRX1-4), 545 
atypical 2-Cys (mammalian PRX5), and 1-Cys (mammalian PRX6) (561, 594, 706). Both types 546 
of 2-Cys PRX utilize the reducing power of NADPH via the Trx/TrxR system to reduce their 547 
active site disulfides, formed upon catalysis with peroxide reduction, back to active dithiols. On 548 
the other hand, 1-Cys PRX, mainly utilize GSH as the reducing agent (706). Furthermore, the 549 
various PRX isoforms exhibit different subcellular localizations (271, 706). As the PRX enzymes 550 
26 
 
are highly abundant, accounting for as much as 1% of soluble cellular protein (673, 706) and are 551 
excessively reactive with H2O2, they are likely to be critical for both oxidative stress protection 552 
as well as redox signaling (562, 616, 698, 699).  553 
 554 
1. Effects of Prx knockout  555 
 556 
Mice lacking Prx1–4 and 6 are viable, but exhibit increased ROS levels and sensitivity to 557 
oxidative insults (300, 375, 389, 461, 484, 683).  In general, both Prx1
-/-
 and Prx2
-/-
 mice appear 558 
healthy and are fertile, but have hemolytic anemia and increased atherosclerotic plaques (339, 559 
518), suggesting that Prx1 and Prx2 protect red blood cells from oxidative stress (375, 484). 560 
Indeed, they exhibit splenomegaly, Heinz bodies in their blood, and morphologically abnormal 561 
red blood cells, which are high in ROS (375, 484). Prx3
-/-
 mice are healthy in appearance and 562 
could grow to maturity, but exhibit elevated intracellular ROS, including in lung tissue (389).  563 
Intratracheal inoculation of lipopolysaccharide to the Prx3
-/-
 mice results in pronounced lung 564 
inflammation (389). Likewise, Prx6
-/-
 mice also appear normal, but are very sensitive to 565 
oxidative insults (461, 683). 566 
 567 
2. Effects of Prx overexpression  568 
 569 
Overexpression of the PRX enzyme genes generally confers protection against different forms of 570 
oxidative stress. For instance, overexpression of Prx3 in heart mitochondria of mice suppressed 571 
cardiac failure after myocardial infarction (440). In addition, the Prx3 overexpressing mice have 572 
lower mitochondrial H2O2 concentrations and are protected against hyperglycemia and glucose 573 
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intolerance (102). Overexpression of Prx2 inhibits the ischemic damage of neurons (56). 574 
Overexpression of PRX4 in the pancreas of mice suppresses the TRAIL-mediated apoptosis, 575 
protects pancreatic islet β-cells against injury caused by single high-dose streptozotocin (STZ)-576 
induced insulitis, and attenuates inflammation (155). When Prx6 is overexpressed, development 577 
of cataract in mouse and rat lenses are significantly delayed (355). These transgenic mice exhibit 578 
extra resistance to the lung injury induced by hyperoxia (687). However, global Prx6 579 
overexpression does not protect against diet-induced atherosclerosis despite lowering levels of 580 
H2O2 (531).  581 
582 
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III. PARADOXICAL OUTCOMES  583 
 584 
Although knockout of several antioxidant enzymes is detrimental and their overproduction 585 
beneficial to health, the opposite impacts have also been increasingly observed. This chapter 586 
describes a series of such apparently “paradoxical” cases that reveal metabolic benefits of 587 
deleting major antioxidant enzymes, or harmful effects of overexpressing them.          588 
 589 
A. SOD Family 590 
 591 
1. Elevated resistance to APAP toxicity by knockout of Sod1  592 
  593 
APAP, also known as acetaminophen or paracetamol, is the active component of Tylenol and 594 
many other over-the-counter analgesics. A life-threatening hepatotoxicity of APAP overdose 595 
depends upon the liver enzyme CYP2E1 (cytochrome P450 2E1) that catalyzes 596 
biotransformation of APAP to a highly reactive intermediate, N-acetyl-p-benzoquinoneimine 597 
(NAPQI), which in turn can cause depletion of hepatic GSH and excessive liver necrosis (306). 598 
Interestingly, genetic deletion of several antioxidant enzymes yields increased APAP resistance 599 
in mice, which has been reported for Gstp1 (255), TrxR1 (see below) and Sod1. 600 
 601 
While an intraperitoneal injection of 600 mg APAP/kg results in 75% mortality in wild-type 602 
mice within 20 h, all such treated Sod1
-/-
 mice survive for the entire 70 h duration of study (379). 603 
Moreover, the Sod1
-/-
 mice survived nearly three times as long as, and showed much less hepatic 604 
injuries, than wild-type mice following both higher (1,200 mg/kg) and lower (300 mg/kg) doses 605 
of APAP injection, respectively. As shown in FIGURE 1, this astonishing resistance to APAP 606 
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intoxication is associated with at least four separate mechanisms. Firstly, these mice have a 50% 607 
reduction in activity of the NAPQI-producing enzyme CYP2E1 (cytochrome P450 2E1) in liver. 608 
The down-regulated CYP2E1 activity thus helps attenuate NAPQI formation and the resultant 609 
GSH depletion and protein adduct formation. Indeed, hepatocytes isolated from Sod1
-/-
Gpx1
-/-
 610 
mice display a lower susceptibility to APAP-induced cell death, but higher susceptibility to 611 
NAPQI toxicity as compared with cells from wild-type mice (754). Secondly, hepatic protein 612 
nitration plays a crucial role in mediating APAP-induced hepatotoxicity (343). Knockout of Sod1 613 
nearly completely blocks APAP-induced hepatic protein nitration (379). This is intriguing as the 614 
enzyme knockout or depletion presumably elicits elevated O2
-
 production and thus subsequent 615 
peroxynitrite formation for protein nitration, provided that NO is available. Strikingly, SOD1 616 
was previously shown to catalyze peroxynitrite-mediated nitrotyrosine formation in vitro (298). 617 
Later, the enzyme was demonstrated to be required for the protein nitration mediated by APAP 618 
or LPS in murine liver (758). Thirdly, compensatory inductions of other protective antioxidant 619 
enzymes (379, 756) and, fourthly a blunted cell death signaling (757) also attribute to the APAP 620 
resistance of the Sod1
-/-
 mice. Seemingly, the above-described Sod1 deficiency-derived 621 
protection against the APAP overdose is cytosolic-specific. The mitochondrial Sod2
+/-
 mice are 622 
actually more prone to the APAP-induced liver toxicity than their wild-type controls, potentially 623 
through prolonged JNK activation, exaggerated mitochondrial dysfunction with nuclear DNA 624 
fragmentation and necrosis (200, 545).  It remains unclear whether Sod2
+/-
 mice are altered with 625 
expression of CYP2E1 and metabolism of APAP. However, SOD2 may serve a more important 626 
role than SOD1 as mitochondrion is a main target of the APAP toxicity. As the protein level of 627 
hepatic CYP2E1 in the Sod1
-/-
 is not altered (379), the activity loss probably results from an 628 
oxidative modifcation. However, another group failed to detect similar decreases in the baseline 629 
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activity of CYP2E1 in Sod1
-/-
 mice, despite conflicting  effects of ethanol on the enzyme activity 630 
between their own studies (133, 329).  631 
 632 
2. Protection against irradiation-induced neuronal damages by knockout of Sod  633 
 634 
Knockout of Sod1 or Sod2 decreases a baseline of neurogenesis, but ameliorates radiation-635 
induced decline of neurogenesis (183, 286) (FIGURE 2). Following irradiation, Sod2
+/-
 mice 636 
preserve normal hippocampal-dependent cognitive functions and normal differentiation pattern 637 
for newborn neurons and astroglia, which otherwise are damaged in irradiated wild-type mice. 638 
However, irradiation leads to a disproportional reduction in newborn neurons of the Sod2
+/-
 mice 639 
following behavioral training, suggesting that Sod2 haploinsufficiency renders newborn neurons 640 
susceptible to metabolic stress (126). In contrast, irradiation of Sod3
-/-
 mice enhances 641 
hippocampus-dependent cognition and decreases hippocampal nitrotyrosine formation (540). 642 
These results suggest that chronically-elevated O2
-
 anion levels and/or the lower production of 643 
H2O2 resulting from Sod3 knockout, may be protective against irradiation-induced damages in 644 
neurogenesis and cognition. In line with this result, overexpression of SOD3 impairs long-term 645 
learning and potentiation in hippocampal area CA1, further suggesting that O2
-
, rather than being 646 
considered exclusively neurotoxic, may also be a signaling molecule necessary for normal 647 
neuronal function (644).The underlying molecular mechanisms and signaling pathways for these 648 
phenotypes await further investigation. Likewise, knockout of Sod1 enhances recovery after 649 
closed head injury-induced brain trauma in mice, which is associated with attenuated activation 650 
of NFκB and subsequent decreased death-promoting signals due to down-regulated H2O2 651 
production (41).  652 
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 653 
3. Neurological disorders associated with overexpression of SOD1/Sod1   654 
SOD1 expression is associated with two types of neurological diseases: Down's syndrome (with 655 
elevated SOD activity) and ALS (associated with SOD1 mutations) (569, 612). Indeed, SOD1-656 
overexpressing mice manifest certain abnormalities that resemble physiological effects seen in 657 
Down's syndrome, including withdrawal and destruction of some terminal axons and 658 
development of multiple small terminals (23, 24), a defect in platelet's dense granule responsible 659 
for the uptake and storage of blood serotonin (580), thymus and bone marrow abnormalities 660 
(524), and an impairment of hippocampal long-term potentiation (201). Meanwhile, SOD1 661 
overexpression causes mitochondrial vacuolization, axonal degeneration, and premature motor 662 
neuron death, and accelerates motor neuron degeneration in mice expressing an ALS-inducing 663 
SOD1 mutant (303). The SOD1 overexpression also impairs muscle function and leads to typical 664 
signs of muscular dystrophy in mice (525, 550). In fact, transgenic mice overexpressing SOD1 665 
display aberrant protein expression profiles in neurons and mitochondria of hippocampus (605, 666 
606), indicating that elevated SOD1 activity in Down's Syndrome is not just a side-effect or a 667 
compensation in response to the increased oxidative stress, but may be part of the cause for the 668 
pathophysiology.  669 
 670 
Overexpression of SOD1 impairs peripheral nerve regeneration and increases development of 671 
neuropathic pain after sciatic nerve injury with a disturbed inflammatory reaction at the injury 672 
site (350), exacerbates abnormalities in hematopoiesis and radiosensitivity in a mouse model of 673 
ataxia-telangiectasia (529), and promotes aging as indexed by mitochondrial DNA deletion in the 674 
acoustic nerve of transgenic mice (120). Neurons from the SOD1 overexpressing mice exhibit 675 
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higher susceptibility to kainic acid-mediated excitotoxicity, associated with a chronic pro-676 
oxidant state as manifested by decreased cellular GSH and altered Ca homeostasis (30). All these 677 
negative impacts, along with known biochemical and neurological mechanisms, of SOD1 678 
overexpression on various neurological disorders are summarized in FIGURE 3.  679 
 680 
In contrast, other studies have shown either negligible effects of Sod1 overexpression on 681 
toxicities induced by neurotoxins including kainite, glutamate and N-methyl-D-aspartate 682 
(NMDA) (347, 729) or even protections against similar insults in vivo (260, 586) and in vitro (53, 683 
92). These seemingly contradictory findings may be confounded in part with differences in 684 
extents of Sod1 overexpression, acute vs. chronic experimental settings, the timing of 685 
observation, and the cellular capacity of H2O2 catabolism at the testing condition. For example, 686 
when treated with a O2
-
 donor, overexpression of SOD1 increases neuronal vulnerability due to 687 
increased H2O2 accumulation, while overexpression of the gene in astrocytes that exhibit a 688 
greater H2O2 catabolism capacity than do neurons actually leads to an increased resistance to O2
-
 689 
toxicity (104). Therefore, the “paradoxical” function of SOD1/Sod1 overexpression in the central 690 
nervous system may largely rely on: 1) whether the generated extra H2O2 results in a burden 691 
beyond affordable cellular clearing capacity; 2) whether the induced burst of O2
-
 is more 692 
detrimental to cell survival than the converted extra amount of H2O2; and 3) whether effects of 693 
the enzyme expression are unrelated to its enzymatic activity.  694 
 695 
4.  Impaired immune functions and detrimental effects by overexpression of SOD1/Sod1   696 
 697 
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Overexpression of SOD1 in intraperitoneal macrophages decreases their microbicidal and 698 
fungicidal activity, along with increased intracellular production and release of H2O2, decreased 699 
extracellular release of O2
-
, and inhibited NO production following endotoxin stimulation (456). 700 
It was intriguing why enzymatically derived NO production became decreased when O2
-
 anion 701 
levels were diminished. The authors noted that nitrocompound metabolism in macrophages was 702 
affected by the overproduction of SOD1, but did not give mechanistic explanations. Possibly the 703 
reduced activities of NFκB and Erk1/2 in the SOD1 overexpressing macrophages, which are 704 
upstream regulators of iNOS, lead to downregulation of iNOS expression and thus lower NO 705 
production. However, this hypothesis remains to be experimentally confirmed.  Transgenic mice 706 
overexpressing SOD1 show no increased resistance to TNFα-induced endotoxic shock (144), but 707 
a higher sensitivity to malaria infection as reflected by an earlier onset and increased rate of 708 
mortality (220), and activation-induced DNA fragmentation in their splenic T cells (513). 709 
 710 
Doubling the expression of SOD1 does not extend, but instead causes a slight reduction of 711 
lifespan in mice (284).  Likely due to elevated chronic oxidative stress, Sod1 overexpression 712 
leads to an increased heart rate variability (646) and accelerates the loss of cone function (668). 713 
Contrary to its protection against most of ischemic injuries, overexpression of SOD1 in the in-714 
utero ischemia/reperfusion in pregnancy led to brain damages in both adult and fetal mice (383). 715 
Sod1
-/-
 mice exposed to chronic ethanol consumption exhibit decreased alcohol dehydrogenase 716 
activity and little induced CYP2E1 activity, which suppresses ethanol metabolism and precludes 717 
the resultant steatosis (133), while these mice are more susceptible to the acute ethanol-induced 718 
liver injury (329). This apparently contrasting impact of Sod1 knockout on injuries associated 719 
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with either acute or chronic ethanol intake underscore the stress-type and/or temporal-720 
dependence of the function and (patho)physiological relevance of this enzyme. 721 
  722 
5. Diverse effects of SOD2/Sod2 overexpression on alcohol intoxication and cancer cell 723 
survival 724 
 725 
While overexpression of Sod2 protects against liver mitochondrial DNA depletion and 726 
respiratory complex dysfunction after alcohol binge exposure via inhibition of the formation of 727 
peroxynitrite (433), the overexpression aggravates prolonged (7 weeks) alcohol intake-induced 728 
hepatic toxicity (368, 433) (FIGURE 4). The prolonged ethanol intake selectively triggered 729 
hepatic iron elevation, lipid peroxidation, respiratory complex I protein carbonyls and 730 
dysfunction, mitochondrial DNA lesion and depletion in Sod2 overexpressing mice. Because 731 
administration of an iron chelator (deferoxamine) prevents all these adverse effects, hepatic iron 732 
accumulation is likely the crucial factor for the metabolic disorder (368). It has been suggested 733 
that alcohol administration decreases the expression of hepcidin, leading to abnormally active 734 
duodenal ferroportin and increased intestinal absorption of iron, which gradually increases 735 
hepatic iron accumulation (246). Although it remains unclear why in the referenced study (368) 736 
the iron overload was only found in Sod2 overexpressing mice, elevated Sod2 activity was 737 
linked to hepatic iron accumulation through modulation of iron homeostasis proteins in alcoholic 738 
patients (481, 633). 739 
 740 
A proposed mechanism for aggravated hepatotoxicity by Sod2 overexpression may be as follows: 741 
the hepatic iron overload could lead to a decreased mitochondrial manganese uptake and 742 
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increased mis-incorporation of iron in the active site, forming Fe-substituted Sod2. The Fe-Sod2 743 
is stable and lacks superoxide dismutase activity, but gains hydroxyl radical generating activity 744 
in the presence of hydroxyl radicals derived from H2O2, which in turn is generated by the 745 
manganese-Sod. Consequently, increased production of hydroxyl radicals could lead to the 746 
above-mentioned lipid peroxidation and other oxidative injuries (368). Apparently, increased 747 
hepatic iron and H2O2 might also generate hydroxyl radicals through Fenton reactions.  The 748 
anticipated diminished O2
-
 anion levels due to Sod2 overexpression might furthermore remove 749 
its beneficial roles in limiting propagation of lipid peroxidation and blunt alcohol-induced 750 
increases of iNOS and subsequent up-regulation of peroxisome proliferator activated receptor 751 
gamma coactivator 1 (PGC-1), which otherwise promotes mitochondrial DNA replication (368). 752 
Another contributing factor could be the decrease in the mitochondrial transcription factor A 753 
(Tfam) in Sod2 overexpressing mice following alcohol administration. However, further studies 754 
are required to clarify the different cause-effect relationships with regards to the observed 755 
phenotypes. It should be noted that in rats, overexpression of Sod2 in liver prevents steatosis, 756 
inflammation, necrosis, and apoptosis following prolonged alcohol (4 weeks) administration 757 
(694). Thus, there may also be different impact between species of Sod2 overexpression on 758 
ethanol metabolism and intoxication. 759 
 760 
Recently, differential roles SOD2 have been proposed between early and late stages of 761 
carcinogenesis. At the early stage, a lower SOD2 level may facilitate transformed phenotypes by 762 
potentiating mitochondrial defects, whereas at the later stage a higher SOD2 level protects cell 763 
from mitochondrial injury and contributes to tumor growth and metastasis (149). The roles of 764 
SOD2 become further complicated when cancer cells are challenged with increased oxidative 765 
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stress. Overexpression of SOD2 in HeLa cervical cancer cells promotes their growth when 766 
growth factors are withdrawal, suggesting that SOD2 may promote tumor-cell survival in vivo at 767 
conditions unfavorable to cell growth by counteracting the intracellular oxidative processes that 768 
can additively impair cell growth and viability (514). Moreover, overexpression of SOD2 769 
promotes survival of cancer cells treated with radiation, cytokines or drugs (263, 387, 432, 469, 770 
632), likely through activation of NFκB and AP-1 signaling by the SOD2-mediated conversion 771 
of H2O2. Therefore, overexpression of SOD2 may promote cancer due to increased cancer cell 772 
resistance to the cytotoxicity of therapeutic treatments.  773 
 774 
B. Catalase 775 
 776 
1. Diabetic developments induced by catalase overexpression  777 
 778 
The β cell-specific overexpression of rat Cat in non-diabetic background mice shows no 779 
detrimental effects on islet function (717) and protects against the diabetogenic effect of STZ (99, 780 
717). However, this type of overexpression provides no protection against cytokine-mediated 781 
toxicity in isolated islets, despite a suppression of ROS formation (99, 717). Interestingly, 782 
overexpression of CAT in mitochondria, compared with that in cytoplasm, confers stronger 783 
protections against the cytokine-induced cytotoxicity in insulin-producing cells (230, 407), 784 
indicating an important role of mitochondrial ROS in the cytokine toxicity of autoimmune 785 
diabetes.  786 
 787 
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Strikingly, β cell-specific overexpression of Cat in nonobese diabetic mice accelerates 788 
spontaneous diabetes onset in males and cyclophosphamide-induced diabetes in both males and 789 
females, and sensitizes isolated islets to cytokine injuries. FIGURE 5 depicts several described 790 
divergent effects of catalase overexpression on susceptibilities to diabetes, but none of these 791 
effects are fully understood mechanistically. There was a down-regulation of Akt/Foxo1/Pdx1 792 
survival pathway in islets associated with the cyclophosphamide-induced autoimmune type 1 793 
diabetes (390). It was suggested that insulin/IGF-1 mediated phosphorylation of Akt might be 794 
down-regulated by PTP-1B (a tyrosine phosphatase) that is inhibited by ROS (H2O2) and 795 
catalase overexpression prevented the ROS inhibition of PTP-1B (390, 574). Although there are 796 
no direct experimental data to support these notions, maintaining adequate intracellular H2O2 797 
may be needed for activating protective responses of β cells in autoimmune type 1 diabetes.  798 
 799 
In contrast, Cat overexpression consistently protects against diabetic nephropathy (58, 603) or 800 
insulin resistance-induced cardiac contractile dysfunctions (160). Overexpression of Cat also 801 
attenuates high glucose-induced reduction of endothelial cell tight-junction proteins and the 802 
subsequent brain blood barrier (BBB) dysfunction in diabetes (402). These data suggest 803 
differential roles of catalase in pancreas and other organs in diabetic vs. physiological conditions. 804 
 805 
2. Cell type-dependent inhibition of proliferation by catalase overexpression  806 
 807 
Elevating catalase activity, similar to that of Sod, may alter the sensitivity of cancer cells to 808 
chemotherapy (216, 416). Overexpressing CAT in the cytosolic and especially in the 809 
mitochondrial compartments of HepG2 cells potentiates TNF--induced apoptosis by promoting 810 
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activation of caspases-3 and -8 (26). In contrast, overexpression of Cat in a murine lymphoid cell 811 
line enhances resistance to dexamethasone-induced apoptosis and exhibits increased net tumor 812 
growth in nude mice, which is associated with a delay of mitochondrial cytochrome c release and 813 
altered glucose and energy metabolism (648, 649). Overexpression of CAT inhibits proliferation 814 
of endothelial cells (740) and vascular smooth muscle cells (66, 602) by suppressing Erk1/2 and 815 
p38 MAPK signaling (602) and promoting a Cox2-dependent apoptosis (66). This highlights the 816 
need for a physiological level of endogenous H2O2 for survival and proliferation of vascular cells. 817 
Interestingly, the proliferation rate is elevated in vascular smooth muscle cells of Sod1
+/-
 and 818 
Sod2
+/-
 mice, along with higher activity of divergent mitogenic signaling pathways.  The 819 
heterozygosity of Sod1 leads to preferential activation of Erk1/2 and p38 MAPK, while that of 820 
Sod2 causes activation of JAK/STAT pathway in smooth muscle cells (422). This opposite 821 
outcome is intriguing, because overexpression of Cat presumably diminishes intracellular H2O2 822 
whose formation would be supposed to be lower due to the Sod haplodeficiency. Nevertheless, 823 
these diverse effects underscore the physiological importance to tightly regulate intracellular 824 
H2O2 levels for control of vascular cell proliferation. Furthermore, specific overexpression of 825 
CAT in myeloid lineage cells impairs perfusion recovery associated with fewer 826 
neovascularization and blunted inflammatory response following a femoral artery ligation, 827 
suggesting that H2O2 derived from myeloid cells such as macrophages plays a key role in 828 
promoting neovascularization in response to ischemia and in the development of ischemia-829 
induced inflammation (269). Notably, decreases of H2O2 levels upon overexpression of catalase 830 
were verified by direct assays in vascular smooth muscle cells and myeloid cells in the above-831 
mentioned studies, but only by indirect methods in endothelial cells and lymphoid cells. 832 
 833 
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C.  GPX Family 834 
 835 
1. Improved insulin sensitivity and decreased insulin synthesis upon knockouts of Gpx1 and 836 
Sod1   837 
 838 
While knockouts of Gpx1 and Sod1 impair islet function, pancreas integrity, and body glucose 839 
homeostasis, these mice present improved insulin sensitivity in liver and muscle (680, 684). This 840 
improvement is mainly associated with an increased phosphorylation of muscle Akt at Thr
308
 and 841 
Ser
473
 after injection of insulin (684) (FIGURE 6). Presumably, this “unanticipated” benefit is 842 
attributed to elevated intracellular ROS that inhibit protein phosphatase activities and thereby 843 
attenuate dephosphorylation of Akt (33, 680).  Moreover, an increased IRβ protein in the liver of 844 
the Sod1
-/-
, but not in the Gpx1
-/-
, mice may also contribute to the improvement (684). 845 
Meanwhile, Gpx1
-/-
 mice are resistant to the high fat diet-induced insulin resistance and show 846 
favorable responses including decreased-expression of gluconeogenic genes (G6pc, Pck1 and 847 
Fp1), increased glucose uptake by white gastric and diaphragm skeletal muscles through 848 
membrane docking of glucose transporter 4 upon AS160 phosphorylation on Thr
642
, and 849 
enhanced insulin-induced oxidation of phosphatase and tensin homolog (Pten) and PI3K/Akt 850 
signaling (406) in their embryonic fibroblast cells.  851 
 852 
Comparatively, the Sod1 knockout exerts stronger impacts on insulin synthesis and secretion, 853 
glucose and lipid metabolism, and islet integrity than that of Gpx1 (684). Simultaneous ablation 854 
of both enzymes does not result in additive or severer metabolic outcomes. The Sod1
-/-
 mice 855 
show more apparent pancreatitis than the Gpx1
-/-
 mice that are more susceptible to the cerulein-856 
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induced amylase increase. Although hypoinsulinemia and decreased pancreatic β cell mass are 857 
caused by knockouts of both of Gpx1 and Sod1 via down-regulation of the key transcription 858 
factor Pdx1 in pancreatic islets, the former seems to decrease only Pdx1 protein whereas the 859 
latter exerts suppressions at three levels of the Pdx1 regulation: epigenetic, mRNA, and protein 860 
(684) (FIGURE 7). Likewise, knockout of Sod1, but not Gpx1, up-regulates protein phosphatase 861 
2b/sterol responsive element binding protein (SREBP)-mediated lipogenesis and down-regulates 862 
the AMPK-mediated gluconeogenesis (680). Apparently, there are several overlapping as well as 863 
distinctive mechanisms for Sod1 and Gpx1 in regulation of glucose homeostasis and lipid 864 
metabolism (378).  It should also be noted that reductive stress may be as destructive as 865 
oxidative stress in the etiology of diabetes and obesity (753).  866 
 867 
2.  Potentiation of the peroxynitrite-induced toxicity by GPX1/Gpx1  868 
 869 
Peroxynitrite represents a major RNS formed from reaction of O2
-
 with NO, which occurs at a 870 
diffusion-limited rate (39). Although peroxynitrite induces nitration in a variety of biomolecules, 871 
a major activity indicator is the nitrosylation of protein tyrosine residues (39). Peroxynitrite-872 
mediated protein nitration is indeed involved in the pathogenesis of many human diseases (297, 873 
530). Impacts and mechanisms of the influence of GPX1 activity on peroxynitrite-induced 874 
oxidative damage have been studied in different systems (198, 610). FIGURE 8 summarizes 875 
“paradoxical” roles and mechanisms of bovine GPX1, Gpx1 knockout, and GPX1 876 
overexpression in coping with the PN-mediated protein nitration and toxicity in these systems. 877 
 878 
Using a cell-free system, Sies et al found that GPX1 can serve as a peroxynitrite reductase (610). 879 
However, that function of GPX1 could not be verified by Fu et al. (198) using primary 880 
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hepatocytes isolated from Gpx1
-/-
 mice. In stark contrast, Gpx1
-/-
 hepatocytes are instead 881 
extremely resistant to peroxynitrite-induced DNA fragmentation, cytochrome c release and 882 
caspase-3 activation, GSH depletion, protein nitration, and cell death (198). Interestingly, 883 
treating hepatocytes with S-nitroso-N-acetyl-penicillamine (SNAP; a NO donor) in addition to 884 
diquat (O2
-
/H2O2 donor) produces synergistic cytotoxicity, and protein nitration induced by these 885 
two pro-oxidants together is attenuated in Gpx1
-/-
 cells (197). While knockout of Gpx1 in mice 886 
exerts partial protection on the APAP- or LPS-induced hepatic toxicity and protein nitration (343, 887 
755, 756), overexpressing GPX1 sensitizes mice to the APAP-induced hepatotoxicity and 888 
lethality (458). The metabolism of APAP in GPX1 overexpressing mice leads to a substantial 889 
decrease in the replenishment of GSH in liver and blood compared with the controls. In contrast, 890 
overexpressing GPX3 and Sod1 in the same study renders mice resistant to the APAP toxicity. 891 
These observations again underscore the complexity or unpredictability of seemingly similar 892 
antioxidant enzymes in coping with a given oxidative insult. 893 
 894 
3.  Protection against kainic acid-induced lethality and seizure by Gpx1 knockout  895 
 896 
Kainic acid is an analog of glutamate that is widely used to induce limbic seizures and model the 897 
disease of epilepsy in rodents (40, 217). Administration of the compound activates NMDA 898 
receptors in hippocampus and other vulnerable brain regions (31, 43). As an event following 899 
NMDA activation (364, 365), there is increased oxidative stress including formations of O2
-
, NO, 900 
and peroxynitrite in the central nervous system after the kainic acid injection (217, 452, 568). 901 
Thus, antioxidants such as ascorbate, GSH and EUK-134 (a synthetic SOD and catalase mimic) 902 
can decrease the neurotoxic effects of kainic acid and its seizure-associated neuropathology (421, 903 
575). Strikingly, Gpx1
-/-
 mice are much more resistant to kainic acid-induced seizure (frequency 904 
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and interval), neuronal injury, and lethality compared with wild-type controls (309). This 905 
increased resistance involves inactivation of the NMDA receptor via thiol oxidation of its 906 
NMDA receptor-1 subunit, possibly due to elevated H2O2 levels in the brain of Gpx1
-/-
 mice, and 907 
subsequent attenuation or block of the kainic acid-induced oxidative injuries  (309) (FIGURE 9). 908 
As described above, neurons from SOD1 overexpressing mice exhibit elevated susceptibility to 909 
the kainic acid-mediated excitotoxicity (30). Therefore, certain levels of ROS or chronic 910 
oxidation in the brain are needed for a functional NMDA receptor, with long-term use of 911 
antioxidants possibly thereby leading to detrimental rather than protective effects.  912 
 913 
4. Type 2 diabetes-like phenotypes induced by Gpx1 overexpression  914 
 915 
Global overexpression of Gpx1 in non-obese or non-diabetic mice results in hyperinsulinemia, 916 
hyperglycemia, hyperlipidemia, insulin resistance, β cell hypertrophy, and obesity at 6 months of 917 
age (445).  Diet restriction can prevent all these phenotypes except for hyperinsulinemia and 918 
hyper-secretion of insulin after glucose-stimulation (686). Thus, these two phenotypes represent 919 
primary effects of Gpx1 over-production and seem to be mediated by up-regulation of a key 920 
transcription factor (Pdx1) for β cell differentiation and insulin synthesis and secretion, as well as 921 
down-regulation of the insulin secretion inhibitor mitochondrial uncoupling protein 2 (Ucp2). 922 
The insulin resistance in these Gpx1 overexpressing mice may be attributed to less oxidative 923 
inhibition of protein tyrosine phosphatases due to diminished intracellular ROS (H2O2) levels 924 
upon higher Gpx1 activity, leading to accelerated dephosphorylation of IRβ and Akt after insulin 925 
stimulation (445, 686). Meanwhile, Gpx1 overexpression also affects transcripts, proteins, and 926 
functions of other pro-insulin genes, lipogenesis rate-limiting enzyme genes, and key glycolysis 927 
(GK) and gluconeogenesis (PEPCK) enzymes in islets, liver, and muscle (526, 721). FIGURE 928 
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10 highlights the major pathways and modes of action in relation to insulin production and 929 
insulin responses, illustrating how Gpx1 overexpression can induce type 2 diabetes-like 930 
phenotypes. Dietary Se deficiency precludes Gpx1 overproduction in these mice and partially 931 
rescues their metabolic syndromes by modulating or reversing these molecular and biochemical 932 
changes (721). Similarly, dietary Se levels have indeed been shown to affect glucose metabolism 933 
and insulin sensitivity (362). However, β cell-specific overexpression of GPX1 in db/db mice 934 
with mutated leptin receptor rescues β-cell dysfunction with reversed signs of diabetes at 20 935 
weeks of age (229, 244). It should be noted that islets have relatively low baseline Gpx1 activity 936 
but display one of the highest overproductions of Gpx1 activity among all tissues in the global 937 
Gpx1 overexpressing mice. Collectively, it seems clear that GPX1/Gpx1 overproduction is 938 
beneficial at diabetic or obese pathophysiological conditions, but becomes deleterious if 939 
triggered in healthy mice with normal metabolic status.   940 
 941 
5. Intriguing roles of GPX enzymes in carcinogenesis 942 
 943 
A number of studies have revealed cancer type-, stage-, and tissue-dependent impacts of GPX 944 
enzymes on carcinogenesis (FIGURE 11). Global GPX1 overexpression sensitizes mice to skin 945 
tumor formation induced by 7,12-dimethylbenz(a)anthracene/12-O-tetradecanoylphorbol-13-946 
acetate (DMBA/TPA) (413), whereas adenoviral delivery of GPX1 to pancreatic tumor 947 
xenografts actually suppresses the tumor growth in nude mice (403). While mechanisms for 948 
differential roles of GPX1 between skin and pancreatic tumors remains elusive, a deficiency of 949 
Gpx1 in cancer-free naked mole rats (323) suggests the enzyme to be dispensable for cancer 950 
prevention at least in this particular species. As discussed in Chapter II, chronic colitis (174) and 951 
inflammation-driven intestinal cancer (118) are observed in Gpx1
-/-
Gpx2
-/-
 mice (118, 174), but 952 
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not in Gpx2
-/- 
mice unless additional stress is employed (678). This implies dose-dependent or 953 
overlapping roles of the two Gpx enzymes in this regard.  954 
 955 
Roles of GPX2 in carcinogenesis vary with cellular metabolic contexts (61, 473). In healthy 956 
(normal or precancerous) cells, the enzyme helps maintain self-renewing of the gastrointestinal 957 
epithelium, suppress inflammatory processes, and thereby inhibit carcinogenesis (61). Loss of 958 
Gpx2 induces apoptosis, mitosis, and elevated Gpx1 expression in the intestine of mice (62, 186). 959 
In cancerous cells, however, the anti-apoptosis function of the enzyme may promote their growth 960 
and migration. After being treated with intestinal carcinogens azoxymethane/dextran sulfate, 961 
Gpx2
-/-
 mice fed a selenium-inadequate diet (0.08 mg Se/kg) showed increased tumor numbers 962 
but decreased sizes, compared with the wild-type controls (352). The elevated tumor numbers 963 
may reflect Gpx2-derived protection against carcinogenesis at the early stage of tumor formation, 964 
whereas the declined tumor sizes imply promotion of Gpx2 on tumor growth during the lates 965 
stages of tumorigenesis.  In addition, up-regulation of GPX2 in colorectal cancer (59, 187) and 966 
activation by cancer-associated NRF2 and Wnt pathways (28, 336) further suggest that the 967 
enzyme may indeed be involved in the pathophysiolical processes.  968 
 969 
Several studies have collectively demonstrated both positive and negative impact of GPX3 on 970 
carcinogenesis (62). While knockout of Gpx3 sensitizes mice to chemical-induced, colitis-971 
associated carcinoma (32), knockdown of the gene by shRNA in leukemia stem cells decreased 972 
their competitiveness and self-renewal capability (256). Apparently, most of the findings on the 973 
roles of GPX enzymes in carcinogenesis await full elucidation of the molecular and cell 974 
biological mechanisms.  975 
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 976 
D. Paradoxical effects of TrxR1 targeting by genetic modulation or drug treatment  977 
 978 
 979 
Although TrxR1 is an essential enzyme for mouse embryogenesis, the enzyme can be 980 
conditionally deleted in a wide range of differentiated tissues without apparent phenotype (Table 981 
8, see above) and fully inhibited for at least a week in mice by gold compound treatment without 982 
overt toxicity (615).  Strikingly, genetic deletion or full inhibition of TrxR1 can instead protect 983 
cells and tissues from oxidative challenges. As in the case of global knockout of Sod1, liver-984 
specific Txnrd1
-/-
 mice become highly resistant to APAP-induced hepatotoxicity (302, 520). It 985 
was also found that the TrxR1 enzyme, together with GSH, is a prime target for inhibition by 986 
NAPQI, which should help explain why APAP-derived NADPQI becomes more toxic than what 987 
is seen upon mere GSH depletion using inhibition of GSH synthesis (302, 520). The protective 988 
effects of TrxR1 deletion against APAP challenge are likely to be explained by compensatory 989 
up-regulation of many Nrf2 targets in mice with hepatocytes lacking Txnrd1 with more robust 990 
GSH biosynthesis, glutathionylation, and glucuronidation systems following APAP overdose 991 
(302, 520). Indeed, “priming” of tissues for oxidative injuries by prior inhibition of TrxR1 has 992 
also been shown in lung tissue, where inhibition of the enzyme leads to better resistance to 993 
hyperoxia (63, 405), in most or all of these cases presumed to involve activation of the cell 994 
protective Nrf2 pathway (89). 995 
 996 
Similar paradoxical roles of TrxR1 exist in carcinogenesis. Although liver-specific Txnrd1
-/-
 997 
mice were reported to display a much greater tumor incidence (90 vs 16%) compared with wild-998 
type mice after diethylnitrosamine induction (79), the Trx/TrxR1 system has also been found to 999 
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promote tumor growth (19, 251).  Tumors arising in mice after injection of Txnrd1-knockdown 1000 
Lewis lung carcinoma (LLC1) cells are of much smaller in size than those from mice injected 1001 
with the control, malignant cells; and most importantly, these knockdown LLC1 cells lose their 1002 
targeting construct or show attenuated metastasis (251, 730). The mechanisms by which the 1003 
enzyme can either be cancer preventive or promoting cancer progression are not fully understood, 1004 
but are likely to relate to different stages of carcinogenesis and perhaps also differ between 1005 
cancer types. It is known that over-expression of TrxR1 in cancer cells correlates with 1006 
tumorigenic properties and down-regulation of the enzyme inhibits growth of human 1007 
hepatocarcinoma cells (204). As mentioned above, knockdown of TrxR1 in lung carcinoma cells 1008 
reverses their tumorigenicity and invasive potential in a xenograft model (730). Therefore, 1009 
TrxR1 enzymes have been suggested as potential targets for development of anticancer drugs 1010 
(410, 485, 666). As loss of Txnrd1 renders tumors highly susceptible to pharmacologic GSH 1011 
deprivation, a concomitant inhibition of both GSH and TxrR systems was recently proposed to 1012 
be a strategy to kill tumor cells (245, 430). In this context it should be noted that drug-targeted 1013 
inhibition may not only inhibit TrxR1, but can also convert the enzyme to a pro-oxidant NADPH 1014 
oxidase upon selective modification of its Sec residue (13).  1015 
 1016 
We conclude that TrxR1 can exert “paradoxical” effects in three separate forms of the enzyme, 1017 
i.e. no matter whether it is overexpressed, knocked down or targeted by low molecular weight 1018 
inhibiting compounds, either beneficial or detrimental physiological effects can be triggered 1019 
depending upon cellular context. This is summarized in FIGURE 12 and its diverse effects 1020 
should be considered in studies aimed at understanding the physiological roles of this enzyme.  1021 
 1022 
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2.  E.  Hazard of Trx overexpression and benefit of Grx knockout  1023 
 1024 
Increased Trx1 potentiates cadmium toxicity (218), whereas ablation of Grx1 renders mice 1025 
resistant to the LPS- induced inflammation and macrophage activation associated with enhanced 1026 
S-glutathionylation (4). The latter also enhances resolution of airway hyper-responsiveness and 1027 
mucus metaplasia in allergic mice (270). Because the gene knockout also attenuates 1028 
inflammation and expression of proinflammatory mediators in the lung, S-gluathionylation of 1029 
specific target proteins may be beneficial to attenuate airway hyperrepsonsiveness like in asthma. 1030 
Thus, inhibitors of Grx1 may be of interest clinically.  Plasma Grx1 concentration is increased in 1031 
patients with diabetes (163). This may be linked to defective revascularization in diabetes, since 1032 
Grx1 overexpressing mice have elevated soluble vascular endothelial growth factor receptor 1 1033 
and attenuated post-ischemia limb revascularization (478).  1034 
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IV. MECHANISMS AND METABOLIC RELEVANCE   1035 
 1036 
The apparently paradoxical outcomes in several cases of antioxidant enzyme overexpression or 1037 
genetic deletion studies clearly challenge the “prevailing” view that these enzymes are only 1038 
beneficial, or that ROS/RNS are solely toxic byproducts of aerobic metabolism. It is clear that 1039 
controlled production of ROS/RNS is important in signaling and that under certain conditions, 1040 
antioxidant enzymes exhibit pro-oxidant activities. In all aspects of redox biology, spatial-, 1041 
tissue- and temporal-specific dependences are crucial, which will also have an impact upon the 1042 
physiological functions of antioxidant enzymes (307, 465, 656).  1043 
 1044 
The exact mechanisms for “paradoxical” outcomes of antioxidant enzyme knockout or 1045 
overexpression should undoubtedly derive from the interplay of three factors: 1) the properties 1046 
and roles of their ROS/RNS substrates and products; 2) the activities and functions of the 1047 
antioxidant enzymes and 3) the metabolic contexts in which these entities interact. Accordingly, 1048 
we will here discuss a series of chemical, molecular, biochemical, and physiological mechanisms 1049 
that need to be considered and that may help to explain the observed paradoxical roles of 1050 
antioxidant enzymes. Contributions of reductant substrates such as GSH to the paradox are 1051 
discussed in the context of antioxidant enzyme catalysis.   1052 
  1053 
A. Multi-faced Chemical Reactivity and Metabolic Roles of ROS/RNS 1054 
 1055 
1. Dose-dependent impacts of ROS/RNS  1056 
 1057 
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Whereas excessive levels of ROS and RNS trigger oxidative stress, appropriate levels of 1058 
ROS/RNS are required for redox signaling. Apparently, antioxidant enzymes are needed to 1059 
suppress excessive production of ROS and RNS. Under certain conditions, however, insufficient 1060 
ROS/RNS or elevated cellular reductants can be detrimental, or, conversely, elevated ROS/RNS 1061 
may be beneficial. This explains in part dose-dependent effects of ROS/RNS or roles of their 1062 
metabolizing enzymes. Transgenic mice with 2- to 3-fold increased Sod2 activity in major 1063 
organs are phenotypically normal and fertile (542), while a higher overexpression of the enzyme 1064 
to 2.5- to 8.7-fold activity above normal decreases body size and female fertility, and causes 1065 
male infertility. Transgenic lines overexpressing 60- or 100-fold catalase activity are more 1066 
resistant to doxorubicin-induced cardiac injury, but further overexpression to 200-fold or higher 1067 
fails to provide protection (319). While the precise molecular explanations to these observations 1068 
are unknown, they likely involve effects of site-specific localization, reactivity, steady-state 1069 
levels of H2O2, as well as differential induction of compensatory pathways, as discussed below.  1070 
 1071 
2. Detrimental effects of insufficient peroxides on redox signaling 1072 
 1073 
Of the primary ROS, H2O2 is perhaps the most important for signaling (560), with both O2
-
 and 1074 
hydroxyl radicals having limited half-life and reactivity profiles unsuitable for diffusible signals 1075 
(135, 192, 193). H2O2 is an ideal signaling agent because of its relatively long lifetime and 1076 
selectivity for targeting of particular protein microenvironments (135, 181, 192, 193, 700). It can 1077 
oxidize thiol groups of specific Cys residues to disulfides (S-S), sulfenic (S-OH), sulfinic (SO2H), 1078 
and sulfonic (SO3H) acids (404). Over-oxidation to sulfonic acid is not implicated in redox 1079 
signaling, but contributes to oxidative stress due to its irreversibility. Peroxide sensing proteins 1080 
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that utilize uniquely reactive Cys residues may include transcriptional factors (20, 487), kinases 1081 
(651), phosphatases (451), ion channels (521), ubiquitin and small ubiquitin-related modifier 1082 
(SUMO)-conjugating enzymes, ligases and adapter proteins (55, 157, 450, 743), as well as 1083 
various metabolic enzymes (466).  Most likely of all proteins to react with H2O2 are however 1084 
peroxidases, such as GPXs or PRXs, which in turn may propagate the oxidative signal to specific 1085 
downstream targets in cells (698, 699).  1086 
 1087 
Many signal transduction pathways are hard-wired to redox signaling networks, due to the large 1088 
number of kinases and phosphatases having reactive Cys residues that affect their activities (70, 1089 
192, 193, 673). Deliberately-produced peroxides can oxidize catalytic Cys residues in various 1090 
protein tyrosine phosphatases (PTPs), thereby inactivating them (34, 146, 577, 650, 670). This in 1091 
turn serves to enhance activation of related signaling pathways by preventing the PTPs-catalyzed 1092 
de-phosphorylation of specific phosphorylated tyrosine residues. Apparently, this type of 1093 
inhibition can be removed by a hyperactivity of peroxide-scavenging enzymes. As in the case of 1094 
Gpx1-overexpressing mice that develop type 2 diabetes-like phenotypes (445, 686), the over-1095 
produced Gpx1 diminishes intracellular ROS production, reverts the inhibition of PTPs, 1096 
accelerates dephosphorylation of IR and Akt after insulin stimulation, and thereby leads to 1097 
insulin resistance. In contrast, knockout of Gpx1 causes accumulation of intracellular peroxide, 1098 
which, via the same pathways, improves insulin sensitivity and renders the mice more resistant to 1099 
high-diet induced insulin resistance (406, 684). However, the specific dose, temporal dynamics, 1100 
and targeting protein phosphatases for the action of H2O2 in redox signaling remain largely 1101 
unclear. 1102 
 1103 
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3. Mixed effects of peroxynitrite in cell signaling  1104 
 1105 
Peroxynitrite-mediated signaling pathways are not as firmly established as those involving H2O2. 1106 
Traditional “antioxidant” ROS-scavenging enzymes like SOD1 and GPXs have been implicated 1107 
in peroxynitrite metabolism and are supposed to affect the related signaling pathways. 1108 
Peroxynitrite can upregulate Src tyrosine kinases, the Akt pathway, and various mitogen-1109 
activated kinases (512). Because many mitogen-activated kinases like p38 and c-Jun are 1110 
implicated in pro-apoptotic pathways, peroxynitrite is considered to be a pro-death signaling 1111 
molecule. In addition, peroxynitrite has also been implicated in hypoxic signaling. Under 1112 
hypoxia, cytochrome c oxidase exhibits nitrite reductase activity, reducing nitrite to nitric oxide 1113 
instead of oxygen to water (85, 86). This nitric oxide then reacts with O2
-
 to form peroxynitrite, 1114 
which can oxidize yet to be determined protein targets that signal adaptation to hypoxia (158, 1115 
534). As discussed in greater detail below, SOD1 can either increase or decrease peroxynitrite 1116 
via its ability to control O2
-
 fluxes. Thus, paradoxical outcomes of Sod1 knockout or SOD1 1117 
overexpression may be in part derived from the unpredictable consequences of peroxynitrite 1118 
modulation (298, 512, 758). The same may also be true for the case of GPX1 (197-199) but the 1119 
precise roles and mechanisms of SOD1 and GPX1 in regulating peroxynitrite-mediated signaling 1120 
are unclear.  1121 
 1122 
B.  Paradox-related Properties of Antioxidant Enzymes 1123 
 1124 
1. Pro-oxidant catalysis  1125 
 1126 
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Despite their well-known ROS/RNS scavenging capacity, some antioxidant enzymes may also 1127 
promote oxidative/nitrosative stress. One example is the conversion of TrxR1 to a prooxidant 1128 
enzyme upon targeting of its Sec residue by inhibitors, as discussed above. Another illustrative 1129 
example relates to the peroxidase activity exhibited by SOD1 (398, 399, 551, 745). The 1130 
peroxidase cycle of SOD1 involves peroxide reducing the Cu(II) center to form O2
-
 radical and 1131 
Cu(I), followed by another molecule of peroxide re-oxidizing Cu(I) to form Cu(II) and hydroxyl 1132 
radical. These reactions can occur under severe peroxide stress, with the resulting hydroxyl 1133 
radicals subsequently being able to irreversibly oxidize metal coordinating His residues and 1134 
thereby inactivate SOD1 (728). In the presence of carbonate, hydroxyl radicals can also oxidize 1135 
carbonate to form carbonate radicals, which can in turn oxidize a variety of other substrates, 1136 
including azide, urate, and nitrite (448, 745). However, it remains unclear to which extent this 1137 
chemistry happens in vivo, but how much this contributes to the SOD1 toxicity. 1138 
 1139 
In some circumstances, SOD1 can also promote aberrant protein nitration, either by enhancing 1140 
peroxynitrite production or by directly activating it for tyrosine nitration. Beckman and 1141 
colleagues demonstrated that human SOD1 mutants that are zinc deficient, either due to 1142 
mutations associated with ALS or by other interventions that limit zinc to the protein, are better 1143 
at catalyzing the reduction of dioxygen to O2
-
, thus providing a pool of O2
-
 that can react with 1144 
nitric oxide to form peroxynitrite (173, 655). This peroxynitrite can then go on to nitrosylate and 1145 
irreversibly damage various biomolecules, serving as another mechanistic basis for a toxic gain 1146 
of function associated with various ALS-associated the mutants of SOD1.  1147 
 1148 
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Beckman and Koppenol have also proposed that intact human SOD1 can activate peroxynitrite to 1149 
nitrosylate protein tyrosine residues (38, 39). The mechanism would involve Cu(II)-catalyzed 1150 
heterolytic cleavage of peroxynitrite into the nitronium cation and CuO, with the former being a 1151 
potent nitrosylating agent. Indeed, Lei and co-workers demonstrated that there is a diminished or 1152 
blocked protein nitration in Sod1
-/-
 mice treated with APAP (379). They proposed that the block 1153 
of hepatic protein nitration in those mice might partially explain their resistance to the APAP 1154 
overdose. Adding functional holo-SOD1, but not apo-SOD1, to liver homogenates of the Sod1
-/-
 1155 
mice mixed with a bolus of peroxynitrite indeed resulted in increased protein nitration (758). 1156 
 1157 
Likewise, GPX1 bears pro-oxidant potential. Several groups have demonstrated that this enzyme 1158 
can aggravate nitrosative stress in mouse models (199, 343, 376, 377, 379, 458). This effect 1159 
opposes the role of GPX1 in preventing nitrosative stress by catalyzing reduction of peroxynitrite 1160 
into nitrite using reducing equivalents from GSH (610). Although the precise mechanisms 1161 
remain poorly understood (191, 197), attenuated protein nitration should help explain the 1162 
increased resistance of Gpx1
-/-
 hepatocytes to peroxynitrate toxicity and lack of potentiation or 1163 
even protection conferred by Gpx1 knockout against APAP hepatotoxicity (199, 343, 376, 377, 1164 
379, 458).    1165 
 1166 
2. “Unwanted” modulation of reducing equivalents  1167 
 1168 
Excessive enzymatic removal of ROS/RNS may lead to other detrimental downstream effects. 1169 
For example, consumption of GSH as a reductant substrate deplete cells of GSH and thus 1170 
outweigh the benefits of GSH-dependent ROS scavenging enzymes (199, 379, 458). Although 1171 
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un-catalyzed reduction of peroxide by GSH is slow
 
(700), GPX1 is very efficient at catalyzing 1172 
this reaction (235). However, GSH can directly scavenge other more reactive species, like 1173 
hydroxyl radicals, HOCl, peroxynitrite, and carbonate radicals (235). It can also regenerate 1174 
antioxidants vitamins C and E. This may partially explains why overproduction of GPX1/Gpx1 1175 
can result in greater sensitivity to the destructive reactivity of APAP metabolites (199, 379, 458). 1176 
  1177 
Meanwhile, elevating GSH may also be detrimental via mechanisms that involve S-1178 
glutathionylation and inactivation of various key proteins. For instance, GAPDH (462), eNOS 1179 
(96, 431), certain tyrosine phosphatases (1), MAPK phosphatase 1 (331), mitochondrial 1180 
thymidine kinase 2 (630), and protein disulfide isomerase (715) have all been reported to be 1181 
inactivated by glutathionylation. This may either protect such enzymes from further damage, but 1182 
can inhibits their function. While the precise pathways and mechanisms are yet unclear, NRF2 is 1183 
emerging as a major regulator of oxidative and reductive extreme conditions in metabolism (57, 1184 
321). Upon a rise of ROS levels above normal, NRF2 helps to up-regulate GSH synthase and 1185 
GSSG reductase, G6PD of the pentose phosphate pathway, as well as antioxidant enzymes like 1186 
TrxR1, SOD and catalases. While initially activated to protect against oxidative stress, 1187 
hyperactivity of NRF2 can however result in a shift towards reductive stress, due to over-1188 
abundance of anti-oxidant factors and GSH that can lead to cardiomyopathy and hypertrophy 1189 
(543). It is possible that the detrimental effects of reductive stress can be associated with elevated 1190 
S-glutathionylation (227) and/or inappropriate suppression of critical ROS-dependent signaling 1191 
pathways. The effects of antioxidant enzyme overexpression in this context remain to be better 1192 
characterized. 1193 
 1194 
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3. Stress source and intensity-dependent roles  1195 
  1196 
As ROS scavengers, both Gpx1 and Sod1 protect mice against the lethality and toxicity caused 1197 
by ROS-generating diquat and paraquat (111, 113, 168, 199). However, the opposite is true when 1198 
mice are treated with the RNS-generating APAP and kainic acids (309, 379). Indeed, the 1199 
ultimate metabolic outcome from overexpression or knockout of a particular antioxidant enzyme 1200 
should be decided by how the enzyme will alter the relative production and fate of ROS and 1201 
RNS in a given context. Good examples are the impacts of SOD overproduction on 1202 
cardiovascular diseases or myocardial ischemic injuries. First, elevated SOD may help to 1203 
preserve NO bioavailability, by preventing its reaction with O2
-
 to form peroxynitrite, and thus 1204 
allow NO to serve as a vessel relaxation factor to protect the cardiac function and survival (83, 1205 
493). On the other hand, the hyperactivity of SOD may promote formation of H2O2 which then 1206 
triggers downstream signaling responses that may inhibit vascular pathogenesis (747). However, 1207 
the role of vascular H2O2 can also depend upon the location, as exemplified with H2O2 derived 1208 
from overproduced SOD3 anchored to endothelial cells, which promotes VEGFR2 signaling and 1209 
then potentially aggravates angiogenesis-dependent vascular diseases (508). 1210 
 1211 
Knockouts of Txnrd1, Gpx1 and Sod1 produce different phenotypes of glucose and lipid 1212 
metabolism in mice (302, 680, 684). While the knockout of Sod1 elevates endogenously-derived 1213 
intracellular O2
-
, the mice display similar impairments in islet physiology, but distinct signaling 1214 
mechanism compared with the Gpx1
-/-
 mice with elevated intracellular peroxides. As shown in 1215 
FIGURE 7, Sod1 knockout down-regulates Pdx1 at three levels: epigenetic, gene, and protein, 1216 
whereas the Gpx1 knockout affects only the Pdx1 protein. Interestingly, both knockouts suppress 1217 
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GSIS by elevating Ucp2 expression with decreased ATP production and affecting the 1218 
mitochondrial potential in islets (684). Interestingly, only the GPX mimic ebselen, but not the 1219 
SOD mimic copper diisopropylsalicylate (CuDIPs), rescues impaired GSIS in islets of all test 1220 
genotypes including Gpx1
-/-
 and Sod1
-/- 
(684). The effects of ebselen seemed to be mediated via 1221 
peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1α) while, in 1222 
contrast, CuDIPs improves insulin secretion only in Sod1
-/-
 islets with suppressed gene 1223 
expression of the PGC-1α pathway (685). These results demonstrate that Gpx1 and Sod1, via 1224 
their respective ability to modulate different species of ROS, can differentially affect redox-1225 
sensitive pathways in regulating GSIS. However, the “sensor” in the target signal molecules or 1226 
regulators that distinguish and react with the local changes of O2
-
 and peroxide needs unveiling.    1227 
 1228 
Even for the same oxidative insult, the necessity and mechanism of a given antioxidant enzyme 1229 
will vary with stress intensity and antioxidant status. When mice are injected with a high dose of 1230 
paraquat (50 mg/kg body weight) or diquat (24 mg/kg), Gpx1 becomes absolutely essential to 1231 
promote mouse survival by protecting against the depletion of NADPH and redox collapse (113, 1232 
195). In contrast, Gpx1
-/-
 mice tolerate low doses of paraquat (12.5 mg/kg) and diquat (6 mg/kg) 1233 
well if they are fed adequate selenium to saturate the expression of other selenoproteins (111, 1234 
196). Still, minute amounts of Gpx1 activity, raised by injection of selenium in selenium-1235 
deficient mice, becomes protective against a moderate dose of paraquat-induced hepatic necrosis 1236 
and apoptosis (112). Comparatively, knockout of Sod1 in the mice enhances sensitivity to 1237 
oxidative injury induced by a similar dose of paraquat (10 mg/kg) (264), implicating that 1238 
generation of O2
-
 contributes more to the paraquat-induced oxidative toxicity. 1239 
 1240 
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4. Compensatory inductions  1241 
 1242 
“Hidden helpers” or compensatory responses induced by altering the expression of antioxidant 1243 
enzymes may also help to explain the mechanisms of the observed phenotypes. The protection 1244 
conferred by the Sod1 knockout against the APAP toxicity is associated with a 50% activity 1245 
reduction in a key APAP-biotransforming enzyme, CYP2E1 (379), which catalyzes the 1246 
formation of toxic metabolites of APAP. The Sod1 knockout also results in a 40% reduction of 1247 
GPX1 activity (684), which may also add to the resistance of the Sod1
-/-
 mice to the drug 1248 
overdose (756).  1249 
 1250 
As elaborated above, NRF2 is a redox-sensitive transcription factor that controls protective 1251 
responses to oxidative stress (419, 463). The protein is normally sequestered in the cytosol by 1252 
Keap1 and marked for proteasomal degradation. Under oxidative stress, Keap1 becomes 1253 
oxidized and NRF2 can then translocate to the nucleus where it initiates transcription of selected 1254 
antioxidant enzyme genes (419, 496). In the Sod1
-/-
 mice, a greater fraction of Nrf2 is localized 1255 
in the nucleus and up-regulates gene expression of many antioxidant proteins including 1256 
glutathione S-transferases, sulfiredoxins, TrxR1, GSH synthases and other reductases (239). The 1257 
up-regulation of these enzymes provides an increased antioxidant capacity in Sod1
-/-
 mice against 1258 
the APAP-derived oxidative stress. Likewise, the liver specific knockout of Txnrd1 enhances 1259 
mouse resistance to the APAP toxicity by up-regulation of the Nrf2-target genes and proteins, 1260 
with more robust GSH biosynthesis, glutathionylation, and glucuronidation systems (302, 520). 1261 
The increased resistance to acute lung injury induced by endotoxin in acatalasemic mice (759) 1262 
results from the H2O2-mediated down-regulation of cytokine expression in macrophages via 1263 
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inhibition of NFκB activation.  With these compensatory mechanisms revealing intricate 1264 
pathways of physiological coordination to cope with redox imbalances, caution should be given 1265 
to evaluate functions of antioxidant enzymes as absolute or isolated entities, as they will always 1266 
be context-dependent.  1267 
 1268 
5. Overlapping and coordinated functions  1269 
 1270 
Catalase and GPX1 are two major antioxidant enzymes that are both responsible for removal of 1271 
H2O2 although via distinct mechanisms (94, 184).  Double-knockout mice deficient in both of 1272 
these enzymes were generated to reveal insights into the overlap between these potentially 1273 
redundant H2O2-detoxification systems (333).  Interestingly, hepatic lipid peroxidation is not 1274 
elevated in mice deficient in Gpx1 alone compared with that of wild-type mice (113), yet it is 1275 
increased in mice lacking both Gpx1 and catalase (333).   1276 
 1277 
In other cases, intrinsic expression of multiple isoforms of the same antioxidant enzymes in cells 1278 
makes interpretations of oxidant-mediated diseases difficult. GPX1 is ubiquitous in all types of 1279 
cells and GPX2 is in epithelium of the gastrointestinal tract (60, 117, 177).  Gpx1
-/-
 and Gpx2
-/-
 1280 
mice are grossly normal.  However, Gpx1
-/-
Gpx2
-/-
 mice develop spontaneous ileocolitis and 1281 
intestinal cancer (118, 174, 175).  This occurrence of cancer is also associated with an increased 1282 
rate of mutation in the intestine (372).  Collectively, these results suggest that the two enzymes 1283 
cooperatively attenuate intestinal flora-induced inflammation by removing H2O2 and alkyl 1284 
hydroperoxides, thereby suppressing the vicious cycles of the inflammatory response and 1285 
oxidant-mediated mutations and cancer. 1286 
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 1287 
Over-production of either SOD2 or Cat , each having its distinct target of ROS, in pancreatic β 1288 
cells of mice significantly delays but does not prevent the onset of diabetes induced by STZ 1289 
compared with wild-type mice (99).  However, the STZ-triggered increase in blood glucose is 1290 
more effectively attenuated by overexpression of both enzymes in mice, suggesting that both O2
-
 1291 
and H2O2 contribute to the dysfunction and death of pancreatic β cells caused by STZ.  In 1292 
contrast, double knockouts of Sod1 and Gpx1 did not produce more aggravated effects than the 1293 
single knockout of Sod1 on mouse susceptibility to pro-oxidant toxicity, loss of islet beta cell 1294 
mass and insulin synthesis, and dysregulation of glucose metabolism (376, 684, 758).  Thus, 1295 
overlapping or coordination between antioxidant enzymes is not a universal feature. 1296 
 1297 
Double knockouts of antioxidant enzymes can also yield unexpected novel insights into 1298 
mammalian redox control. This was recently exemplified when Txnrd1 was conditionally deleted 1299 
from hepatocytes in mice lacking a functional Gsr gene, thus leading to livers lacking both of the 1300 
two major cytosolic NADPH dependent oxidoreductases TrxR1 and GR, presumed to be 1301 
required for essentially all NADPH dependent reductive activities in the cytosol. These mice 1302 
were, surprisingly, found to be both viable and fertile. The reductive power was instead supplied 1303 
solely by dietary methionine that became converted to GSH, which was likely used in single-1304 
turnover reactions and thus these livers avoid the reliance on NADPH (171).  1305 
 1306 
6. Non-redox functions  1307 
 1308 
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SOD1 has been shown to play roles in copper and zinc metabolism (132, 690, 709). In Baker’s 1309 
yeast, overexpression or deletion of SOD1 affects the cell resistance or sensitivity to copper and 1310 
zinc toxicity or deprivation, respectively (132, 709). More recent work suggests that SOD1 is 1311 
also important for communicating the cellular stress response to low zinc (278, 709). Most 1312 
interestingly, a group have demonstrated (656) a role for SOD1 in cell signaling independent of 1313 
its role in O2
-
 disproportionation. They found that under oxidative stress, SOD1 translocated to 1314 
the nucleus where it acted as a transcriptional activator of genes involved in oxidative resistance 1315 
and repairing.  Indeed, yeast cells expressing an allele of SOD1 that cannot get into the nucleus 1316 
are more sensitive to oxidative stress. SOD1 represents ~1% of total cellular protein (~10-50 1317 
µM), and less than 1% of total SOD1 enzyme may be needed to protect against various oxidative 1318 
insults (127, 557). Thus, the recently-discovered novel functions of SOD1, besides O2
-
 1319 
scavenging, help explain its high cellular abundance and perhaps its paradoxical roles. 1320 
 1321 
Another antioxidant enzyme that exhibits non-redox functions is PRX1 (307). The enzyme forms 1322 
oligomeric species that exhibit chaperonin activity upon oxidation of certain Cys to sulfinic acid. 1323 
Such a mechanism enables the PRX family enzymes, which are better at scavenging low 1324 
concentrations of peroxide, to be converted to chaperones to ensure proper protein folding under 1325 
severe oxidative stress and high peroxide fluxes (409, 560, 705). Undoubtedly, the discovery of 1326 
SOD1 as a novel transcriptional factor and PRX1 as a chaperone offers a new direction to 1327 
elucidate the underlying mechanism for paradoxical roles of antioxidant enzymes.  Additional 1328 
non-redox functions of antioxidant enzymes include the role of Gpx4 as a structural protein in 1329 
sperm mentioned above, or the cytokine-like properties of extracellular Trx1 or Trx80. It is 1330 
possible, perhaps even likely, that additional non-redox related functions of classically 1331 
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considered antioxidant enzymes will be discovered, which should help in interpreting the 1332 
phenotypes seen upon their genetic deletion or overexpression. 1333 
 1334 
C. Metabolic Context and Reaction Environment Affecting Roles of Antioxidant Enzymes 1335 
 1336 
1. Physiological vs. pathophysiological conditions 1337 
  1338 
Antioxidant enzymes may exert different impact in physiological compared to pathological 1339 
processes. While overexpressing Gpx1 induces type 2 diabetes-like phenotypes in mice without 1340 
diabetic or obese-prone genetic background (445), the β cell-specific overexpression of GPX1 in 1341 
ob/ob mice actually, in stark contrast, reverses hyperglycemia and improves β-cell volume and 1342 
granulation (244). Similarly, knockout of Gpx1 impairs insulin synthesis and secretion in mice 1343 
fed the normal diet (684), but enhances mouse resistance to a high-fat diet-induced insulin 1344 
resistance (406). Therefore, roles of antioxidant enzymes under “normal” and “diseased” 1345 
conditions should not be extrapolated or inferred from each other.   1346 
  1347 
2. Temporal dependence of physiological effects 1348 
 1349 
Short-term benefits of antioxidant enzyme alterations may lead to long-term harms, and vice 1350 
versa. Indeed, overexpression of Gpx1 alone or in combination with SOD1 and SOD3 protects 1351 
mouse islets from oxidative injury and improves islet graft function (480). However, the long-1352 
term over-production of Gpx1 results in hyperinsulinemia, insulin resistance, and obesity (684). 1353 
In contrast, knockout of Sod1 offers extra resistance to APAP overdose and insulin sensitivity in 1354 
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the young adult mice (379, 684), but leads to hepatocarcinogenesis in later life (167). When the 1355 
hippocampal long-term potentiation (LTP), one of the major cellular mechanisms for learning 1356 
and memory ability, is impaired in young (2-months old) SOD1 overexpressing mice (201), the 1357 
aged (2-years old) transgenic mice actually exhibit an enlarged LTP (316) and consequently a 1358 
better performance in spatial memory (315) compared with the wild-type mice. These 1359 
differences implied a strong age-dependence for the effects of the Sod1 deficiency and/or Sod1-1360 
derived peroxide based on the brain function.  1361 
 1362 
3. Subcellular location-dependence effects  1363 
 1364 
Sub-cellular localizations of particular antioxidant enzymes have profound effects on their roles, 1365 
which need to be considered in interpretations of the mechanistic results. Overexpressing 1366 
extracellular GPX3 protects mice from the APAP toxicity, while the overexpression of 1367 
intracellular GPX1 sensitizes mice to the toxicity (458). Likewise, the β-cell specific 1368 
overexpression of cytoplasmic Cat and the metallothionein gene, but not the mitochondrial Sod2, 1369 
accelerates the cyclophosphamide-induced and spontaneously-developed diabetes in the non-1370 
obese diabetic male mice (390). Overexpression of CAT in mitochondria, but not in the 1371 
peroxisomes or nuclei, extends the median and maximal lifespan of the mice by 20% (584).  This 1372 
indicates that the interactions between ROS/RNS and their metabolizing enzymes should not be 1373 
extrapolated from different subcellular compartments.  1374 
 1375 
Likewise, peroxide-derived from the yeast SOD1 protein that is proximal to a membrane bound 1376 
casein kinase is required to regulate energy metabolism in response to oxygen and glucose 1377 
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availability (557). The yeast SOD1 protein that is not targeted to the cytosol, or other SOD 1378 
isoforms that are targeted to the cytosol like mitochondrial SOD2 or Candida Albicans SOD3 are 1379 
unable to regulate casein kinase signaling. Similarly, a small fraction of cytosolic PRX1 and 1380 
PRX2 is associated with lipid rafts proximal to NADPH oxidase enzymes. Only the lipid raft 1381 
associated PRX1, but not cytosolic PRX1, is found to be phosphorylated at Tyr194 by a protein 1382 
tyrosine kinase (PTK) of the Src family when cells are stimulated by growth factors (705). 1383 
Phosphorylation of PRX1 near membranes has the effect of inactivating the enzyme, which 1384 
promotes peroxide-mediated signals to propagate. 1385 
 1386 
4. Cell-compartmentalization and tissue heterogeneity of transgenes   1387 
 1388 
Different types of cell may not respond the same toward similar changes of antioxidant enzymes.   1389 
While the cardiac-specific overexpression of CAT/Cat generates many benefits for prolonging 1390 
lifespan and protecting against cardiac injuries (208, 317, 660, 712, 748, 749), the same specific 1391 
overexpression in the endothelium shows little protection against myocardial or vascular 1392 
ischemia/reperfusion injury (704). In either tissue-specific overexpression of a given antioxidant 1393 
enzyme, such as catalase in cardiomyocytes and pancreatic β cells (319, 717), or ubiquitous 1394 
overexpression of an antioxidant enzyme in mice, the intended overexpression may be very 1395 
heterogeneous in different types of cells within an organ. Likewise, extents of a global 1396 
overexpression of a transgene in mouse tissues may be restricted to certain organs, but not as 1397 
widely spread as the corresponding endogenous mouse genes or the genes whose promoters are 1398 
used in the transgene constructs (such as the human β-actin promoter) (266, 494, 509, 716, 727).   1399 
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The heterogeneity of transgene expression cannot be appropriately assessed when homogenate of 1400 
the entire organ is used for expression study. To circumvent this problem, large genomic 1401 
fragments containing the genes of interest have been used to overexpress SOD1 and CAT (103).  1402 
However, whether the specificity of transgene expression can also be applied to each individual 1403 
type of cells within each organ is still an open question.  1404 
 1405 
Heterogeneity of transgene expression is also shown even in mice carrying an identical transgene. 1406 
For example, the same 14.5-kb genomic fragment containing the entire human SOD1 gene has 1407 
been used independently by several laboratories to generate transgenic mice (87, 170, 231, 681).  1408 
Although the SOD1 overexpression protects heart against an in vitro model of 1409 
ischemia/reperfusion in two independent lines of transgenic mice, the cell specificity of 1410 
overexpression in these mice is quite different. The gene is overexpressed in both endothelial 1411 
cells and cardiomyocytes in one line of transgenic mice (681), but exclusively in coronary 1412 
vascular cells including endothelial cells and smooth muscle cells but not cardiomyocytes in 1413 
another line (106). Therefore, immune-histochemical studies are needed to identify the types of 1414 
cells expressing the transgene in the target organs, and more than one line of transgenic mice 1415 
carrying the same transgene should be employed in physiological studies to ensure 1416 
reproducibility of the experiments.  The latter approach is even more critical when homozygous 1417 
transgenic mice are used in the experiments, because the transgene occasionally disrupts the 1418 
expression of a normal mouse gene at the site of integration by the mechanism referred to as 1419 
“insertional mutagenesis,” leading to a phenotype that is unrelated to the expression of the 1420 
transgene (708).  As a given antioxidant enzyme may not be sufficiently overexpressed in 1421 
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targeted cells within an organ that are vulnerable to a particular oxidant-mediated injury, a 1422 
negative result does not rule out the enzyme function in defense against the injury in those cells.  1423 
 1424 
Furthermore, the tissue heterogeneity of the transgene expression may also affect human 1425 
implications of findings from a particular animal model.  Noteworthy, SOD3 in human aorta 1426 
accounts for approximately 50% of the total SOD activity, whereas the enzyme in rat aorta 1427 
represents only 5% of the total SOD activity due to a key amino acid difference that affects 1428 
tissue binding in vessels (178, 619). As a result, the rat essentially lacks vascular SOD3 and, 1429 
consequently, the observed protection of SOD3 against vascular diseases in rat models may be 1430 
easily over-interpreted. 1431 
 1432 
5. Genetic background of mouse models 1433 
 1434 
Most transgenic and knockout mice are initially generated in a mixed genetic background (272, 1435 
515) and it will take 10 to 12 generations of backcrossing to become congenic.  Because this 1436 
crossing may take several years, most of the phenotypic studies, at least initially, are performed 1437 
on mice in a mixed genetic background.  Such studies should be interpreted with caution, since 1438 
the genetic background of the mice may contribute to the observed phenotypes. For example, 1439 
strain C57BL/6J (B6) mice are more susceptible to hyperoxia-induced lung injury than C3H/HeJ 1440 
(C3) mice (287). Further studies using linkage analysis have shown that the B6 mice carry a 1441 
nucleotide substitution in the promoter region of the Nrf2 gene (116). This Nrf2 polymorphism 1442 
co-segregates with the susceptible phenotype of B6 mice to hyperoxia. Therefore, when SOD2 1443 
transgenic mice in a B6 X C3 mixed genetic background are used for study of hyperoxia-induced 1444 
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lung injury, tolerance to exposure is determined by both the origin of the Nrf2 allele and 1445 
expression of the SOD2 transgene (266). Therefore, control experiments should be conducted for 1446 
functional studies in mice with the identical genetic background, preferably littermates of the 1447 
experimental mice. 1448 
 1449 
6. Heterozygous mouse models and human relevance 1450 
 1451 
To date, most of the phenotypic studies have been performed using homozygous knockout mice 1452 
(if viable) in comparison with wild-type mice. However, studies using heterozygous mice with a 1453 
partial deficiency may be more relevant to human diseases, since humans being fully devoid of a 1454 
protein or enzyme are very rare. Although relatively limited studies have documented the 1455 
phenotypes of such mice that express approximately a half of the normal amount of enzyme, 1456 
some results are very intriguing. For example, under normal physiological conditions, the time to 1457 
development of malignant tumors in Prx1
+/-
 mice is between those of Prx1
-/-
 and wild-type mice. 1458 
In addition, hemolytic anemia was first observed in the Prx1
+/-
 mice at 12 months of age 1459 
compared with 9 months of the null mice, whereas wild-type mice are free of this disease (484). 1460 
Therefore, a partial deficiency in Prx1 results in phenotypes being intermediate between 1461 
complete deficiency and normal in mice.  On the contrary, while Sod1
-/- 
females show a declined 1462 
fertility (489), the fertility of the Sod1
+/-
 females are normal (264, 443). In response to trauma-1463 
induced dysfunction of mitochondrial respiration in brain, Cat
+/-
 mice are as vulnerable as Cat
-/-
 1464 
mice (268). In contrast, the phenotype of Sod1
+/-
 mice resembles that of wild-type mice in 1465 
response to acute paraquat toxicity (10 mg/kg body weight) (264). Therefore, the effect of a 1466 
partial deficiency in antioxidant enzyme on untreated mice and oxidant-mediated disease models 1467 
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varies from gene to gene. While future research on the physiological role of antioxidant enzymes 1468 
should consider more partial knockdown or knockout models, current findings from the 1469 
homozygous knockout mouse models need to be verified in human studies.  1470 
 1471 
In summary, we have postulated a series of mechanisms in this chapter that should underpin the 1472 
“paradoxical” outcomes of antioxidant enzyme deletion or overexpression. FIGURE 13 1473 
highlights the central concept that effects of antioxidant enzyme modulation arise from a 1474 
complex interplay between the activities of the antioxidant enzymes with their ROS/RNS 1475 
substrates (and reductants such as GSH), as well as the importance of the environmental context 1476 
in which they operate. It is our hope that this figure, along with our deliberations, prompt readers 1477 
to recognize that the mechanisms by which nature masterfully orchestrates these seemingly 1478 
paradoxical events are evolved to maintain redox homeostasis, and are critical towards 1479 
understanding both health and disease.    1480 
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V. HEALTH AND NUTRITION IMPLICATIONS  1481 
 1482 
A.  Antioxidant Enzymes in relation to Human Diseases    1483 
 1484 
Catalase-deficient patients, classified as acatalasemic or hypocatalasemic, are found in many 1485 
countries (495).  These patients can have different alterations of the catalase gene including 1486 
substitution (692, 693), deletion (262), and insertion (222, 225).  Being apparently healthy, 1487 
patients with acatalasemia may display increased risks of a progressive oral gangrene (166, 637, 1488 
638) and type 2 diabetes mellitus, especially in females (223).  Still, the rather common 1489 
occurrence of this autosomal recessive disease and its mild symptomatology suggests that 1490 
catalase has mainly redundant activities with regards to human H2O2 removal pathways.  1491 
   1492 
Two well-known neurodegenerative diseases: familial ALS and Down’s syndrome, exemplify 1493 
the significant health implications of antioxidant enzymes in a “paradoxical” manner. While 1494 
dominantly-inherited mutations of SOD1 gene account for 20% of the familial ALS cases (569), 1495 
the pathophysiology seems to be due to a gain of mutant protein toxicity independent of the 1496 
normal enzymatic activity of SOD1. Several lines of transgenic mice expressing Sod1 mutants 1497 
have indeed displayed pathological characteristics reminiscent of those seen in ALS (67). The 1498 
Down’s syndrome patients usually display a 50% increase in SOD activity (14, 131, 612). 1499 
Although transgenic mouse models have been developed for this disease (23, 24, 524, 580), the 1500 
underlying mechanisms of SOD1 toxicity in Down’s syndrome are not understood (143, 366). In 1501 
addition, mutations of SOD2 in humans are associated with idiopathic cardiomyopathy, sporadic 1502 
motor neuron defect and cancer (261). However, Sod2
-/-
 mice generated by targeted disruption 1503 
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only partially recapitulate these human symptoms; rather, these mice display metabolic 1504 
phenotypes including fatty liver and cardiomyopathy (388). Indeed, polymorphisms of SOD 1505 
enzymes, catalase and GPX1 have been implicated in association with a number of human 1506 
metabolic disorders such as diabetes and cardiovascular diseases, as well as cancers [reviewed in 1507 
(130, 253)] 1508 
 1509 
Altered nutritional selenium intake has long been implied in several diseases that are believed to 1510 
be explained mainly by aberrant selenoprotein functions (554). The first examples of genetically 1511 
and molecularly defined diseases of insufficient selenoprotein synthesis were found to relate to 1512 
mutations in the selenium-binding protein-2 involved in translational insertion of Sec into 1513 
selenoprotein and leading to complex diseases with hypothyroidism as a main symptom (25, 150, 1514 
582). These patients are however only partially deficient in selenoproteins and considering that 1515 
deletion of Trsp and some of the selenoproteins in mice is embryonically lethal (see above) it is 1516 
unlikely that patients would survive with a total lack of selenoprotein synthesis, but additional 1517 
polymorphisms and other aberrations in specific selenoproteins are likely to be discovered in 1518 
relation to disease.  1519 
 1520 
Among the genetic variants of GPX enzymes, GPX1Pro198Leu polymorphism is the most 1521 
studied case. In a small randomized trial with 37 morbidly obese women (BMI > 45), this variant 1522 
precluded the protection against DNA breaks by daily supplementation of one Brazil nut daily 1523 
(290 µg Se/day) for 8 weeks (121). Furthermore, the same variation is associated with decreased 1524 
selenium status in Alzheimer’s patients (75), lowered GPX activity and increased breast cancer 1525 
risk in Danish women (553), predisposition to colorectal adenomas or carcinomas based on the 1526 
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Norwegian cohort NORCCAP (241), and increased prevalence of cardiovascular disease on the 1527 
cohort of 184 Japanese with type-2 diabetes (238). These associations appear to be specific, as 1528 
no such relationship was found between the same variant and the risk of basal cell carcinoma in 1529 
the cohort of 317 Danish (677). Another GPX1 variant (C198T) lowering the enzyme activity 1530 
was identified in the South Indian population, which resulted in increased incidences of type 2 1531 
diabetes (C/T, 1.4-fold and T/T, 1.8-fold) (547). 1532 
 1533 
Several single nucleotide polymorphisms on GPX2 are found to affect Barrett’s esophagus and 1534 
esophageal adenocarcinoma (479). Polymorphisms of GPX3 are known to suppress the 1535 
expression of this gene and serve as a risk factor for thrombosis in cerebral veins (676). In the 3’-1536 
untranslated region of GPX4, the T/C variation at position 718 is linked to cancer susceptibility, 1537 
with the T variant being associated with a lower risk for developing colorectal cancer (44).  1538 
Likewise, polymorphisms in transcription factor binding sites of the PRX6 promoter are 1539 
associated with less favorable overall survival in breast cancer patients (589).  1540 
 1541 
B.  Novel Treatments of Antioxidant Enzyme-related Diseases 1542 
  1543 
The impact of antioxidant enzymes in disease may possibly offer novel treatment options for 1544 
redox-related diseases, provided that the molecular mechanisms are known and can be 1545 
specifically targeted. RNA interference (RNAi) technologies may thus possibly be developed for 1546 
treatment of ALS originated from single nucleotide polymorphisms in SOD1 (472, 569). Mice 1547 
expressing the missense mutant SOD1G93A-targeting shRNA were created to prove the 1548 
principle of therapeutic potential (154, 544, 552, 566, 713).  1549 
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 1550 
Commonly used drugs for treating cardiovascular diseases, such as β-adrenocepter blocker 1551 
carvedilo, ACEs, and statins (2, 738), bear SOD-like activities that suppress O2
-
. A GPX mimic 1552 
may be used to improve GSIS impaired by the GPX1 deficiency (685). Overexpressing one or 1553 
several antioxidant enzyme genes proves effective to prolong the survival of islet graft against 1554 
the anticipated host oxidative attack (480). When large doses of chemotherapeutic agents or 1555 
radiation induce severe oxidative stress, treating the patients with antioxidant enzyme mimics 1556 
may help restore their redox homeostasis (359). 1557 
 1558 
Meanwhile, there have been many studies aiming for virally mediated approaches to increase 1559 
expression of antioxidant enzymes for protective effects in models of hypertension, restenosis, 1560 
myocardial infarction, stroke, and other diseases [see (711) for a review]. For example, a gene 1561 
delivery of antioxidant enzymes such as GPX1 and SOD1 was shown to attenuate oxidative 1562 
stress in the brain of rodent models of HIV-associated neurocognitive disorders, Parkinson's 1563 
disease, and diabetic complications (5, 6, 453, 564). Similarly, gene delivery for expression of 1564 
SOD3 protects against the monocrotaline-induced hypertension in the lung of rats (312). 1565 
However, the safety and efficacy of gene therapy are still a concern, and therapeutic potentials of 1566 
viral delivery of antioxidant enzyme genes to specific tissues remains an open question.    1567 
 1568 
In contrast, inhibiting a given antioxidant enzyme or specifically silencing its gene expression 1569 
may help treat disorders related to a gain of enzymatic function. As stated above, there is a great 1570 
potential of using RNAi to specifically suppress the toxic mutant of Sod1 gene associated with 1571 
ALS (154, 544, 552, 566, 713). In addition, microRNA (miRNA), regulators of mRNA stability 1572 
72 
 
and translation, has been recently proposed as biomarkers for a variety of diseases (449). 1573 
Although numerous miRNAs targeting antioxidant enzymes have been identified in cultured 1574 
cells (243, 682), little is known about the reciprocal interactions between antioxidant enzymes 1575 
and miRNA expression during pathogenesis.  1576 
 1577 
Many types of drug-resistant cancer cells express high levels of antioxidant enzymes such as 1578 
SOD, GPX, and PRX (64, 517). Pre-treating these cells with specific antioxidant enzyme 1579 
antagonists or genetically silencing the target gene shall improve the anti-cancer drug efficacy 1580 
(741). Similarly, pre-conditioning the antioxidant enzyme status may help minimize toxicities of 1581 
commonly used drugs. Theoretically, hepatotoxicity of APAP may be attenuated if the patients 1582 
are treated with TrxR1, SOD1 or GPX1 inhibitors, perhaps along with some GPX3 mimic, 1583 
before administration. This notion is based on the fact that knockout of Txnrd1, Sod1 or Gpx1 1584 
renders mice resistant to the drug-induced protein nitration and toxicity (see above), but 1585 
overexpression of GPX3 protects against APAP hepatotoxicity (458).  1586 
 1587 
Targeting of antioxidant enzymes may possibly also be applied to treat chronic diseases such as 1588 
type 2 diabetes. Insulin resistance is the hallmark of the disease, and is inversely related to the 1589 
oxidative inhibition of protein phosphatases in GSIS. When Gpx1 overexpression diminishes of 1590 
intracellular H2O2 and lifts the oxidative inhibition of protein phosphatases, causing insulin 1591 
resistance (445), knockout of Gpx1 and Sod1 alone or together improved insulin sensitivity via 1592 
the opposite mechanism (684). Therefore, the injected insulin could be more effective in 1593 
lowering blood glucose, if GPX1 and SOD1 are temporarily down-regulated prior to insulin 1594 
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administration. Clearly, such clinical protocols based upon findings from mouse experiments 1595 
need to be studied and duly verified in human studies.  1596 
 1597 
C. Antioxidant Nutrients  1598 
 1599 
1. Perception and mixed outcomes of intervention trials 1600 
 1601 
Antioxidant nutrients in foods often refer to vitamins C and E, carotenoids (particularly β-1602 
carotene), and certain trace elements such as selenium and zinc.  Antioxidants are widely used to 1603 
preserve food and beverages and to promote value-added product sales because of their 1604 
perceived health benefits (182, 233). Indeed, many people believe that “antioxidant is good, 1605 
more antioxidant is better” (234). However, more than 100 nutritional intervention trials 1606 
conducted during the past 20 years (45-47) have shown disappointing outcomes of administering 1607 
high or pharmacological doses of dietary antioxidant nutrients (46, 221, 233, 235, 537). In 1608 
contrast, supra-nutrition of selenium and elevated serum selenium concentrations are associated 1609 
with increased risk of type 2 diabetes (9, 119, 134, 363, 620). Although a re-analysis of the data 1610 
from the large Se and Vitamin E Cancer Prevention (SELECT) trial (400) found the risk for 1611 
increased prevalence of diabetes to be attributed to vitamin E supplementation (340), this 1612 
controversial finding underscores the potential risk of over-dosing antioxidant nutrients. It also 1613 
points out the need for a thorough understanding of selenium biology before large nutritional 1614 
selenium trials are initiated or when their results are to be interpreted (249, 555).  1615 
 1616 
2. Mode of actions by antioxidant nutrients 1617 
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 1618 
Antioxidant nutrients may contribute to overall antioxidant defence and interact with antioxidant 1619 
enzymes in several ways. First, some of these nutrients like vitamins C and E directly scavenge 1620 
ROS and RNS. Secondly, some of them serve as co-factors of antioxidant enzymes. Examples 1621 
include selenium in the form of Sec in GPX, copper, zinc, and manganese in SOD, and iron in 1622 
catalase. Dietary selenium deficiency is related to several diseases as is selenium toxicity (554). 1623 
While iron and zinc deficiencies are quite common, deficiencies of manganese and copper are 1624 
rare in humans. However, supplementing these nutrients to adequate subjects does not likely 1625 
elevate their pertaining antioxidant enzyme activities because the activities are supposed to be 1626 
saturated by those nutrients at the requirement levels. That fact may partially explain the lack of 1627 
positive effects of long-term supplementation of antioxidant nutrients in adequate subjects. 1628 
Thirdly, antioxidant nutrients regulate antioxidant enzyme gene expression and protein 1629 
production. For example, dietary vitamin E seems to down-regulate certain selenoprotein gene 1630 
expressions (282) and up-regulate SOD activity (506). However, optimal intakes of antioxidant 1631 
nutrients for the balance between body antioxidant enzymes and ROS/RNS still remain elusive.       1632 
 1633 
3. Effects of phytochemicals on antioxidant enzymes  1634 
 1635 
Plant foods contain a diverse range of secondary metabolites of bioactive molecules 1636 
(phytochemicals) (380). Although these low molecular weight compounds do not seem to 1637 
decrease systemic oxidative damage, polyphenols, carotenoids and tocopherols may reach high 1638 
concentrations in the gastrointestinal tract and exert effects there (236, 237). Moreover, some of 1639 
these phytochemicals (e.g., polyphenols) can exert pro-oxidant effects.  1640 
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 1641 
As discussed above, NRF2 plays a key role in maintenance of cellular redox homeostasis under 1642 
oxidative stress (49, 328, 464). Phytochemicals such as EGCG, curcumin and isothiocyanates 1643 
may induce oxidative or covalent modification of thiols in cysteine residues of NRF2, resulting 1644 
in dissociation of NRF2 from Keap1 and its translocation to the nucleus where NRF2 can 1645 
regulate gene expression of more than 200 antioxidant and phase II detoxifying enzymes (74, 1646 
252, 645). Thus, using naturally-occurring phytochemicals to up-regulate NRF2 may be a 1647 
strategy for preventing or treating chronic diseases due to insufficient NRF2 activities (49, 156, 1648 
214). However, many of these compounds also inhibit TrxR1 (89) and the resulting long-term 1649 
impact on disease must be better understood before guidelines on prevention through 1650 
supplementation with phytochemicals should be given. 1651 
 1652 
NRF2 can exert different roles in effects of various phytochemicals on cancer prevention and 1653 
development  (29, 35, 145, 420, 460, 464, 488, 596).  Many phytochemicals characterized as 1654 
NRF2 inducers (751) can be either chemopreventive or oncogenic (618). This has promoted 1655 
scientists to search for NRF2 inhibitors. For example, brusatol isolated from the seeds of Brucea 1656 
sumatrana, may inhibit NRF2 and enhance the efficacy of chemotherapeutic drugs in a mouse 1657 
xennograft model (558). A coffee alkaloid trigonelline inhibits NRF2 and renders pancreatic 1658 
cancer cells susceptible to anti-cancer drug-induced apoptosis (16). Meanwhile, NRF2 can act as 1659 
a protooncogene (596), suggested that protective effects of its activities might exist only in 1660 
normal non-cancerous cells and tissues. Overexpression of Nrf2 indeed causes chemoresistance 1661 
(742), whereas NRF2 inhibitors can overcome it (488). The complex nature between interactions 1662 
76 
 
of phytochemicals with NRF2 will require a genuinely-personalized use of such compounds for 1663 
cancer prevention or treatment (49, 210). 1664 
1665 
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VII. CLOSING REMARKS 1666 
  1667 
Strict control of ROS and RNS at physiological levels is essential to avoid disease, neither too 1668 
much nor too little being good. Recently, James Watson hypothesized that several chronic 1669 
diseases such as diabetes, dementias, cardiovascular disease and certain types of cancers may all 1670 
be linked to a failure to generate sufficient ROS (689). Another, complementary, theory is the 1671 
Triage theory proposed by Bruce Ames underscoring that distortions in trace element usage by 1672 
age underpins several diseases, which thereby also includes effects on several antioxidant 1673 
enzymes (10, 444).  1674 
 1675 
In this review, we have attempted to provide comprehensive analyses of the paradoxical 1676 
functions of SOD, catalase, GPX, TrxR, Trx, Grx, and PRX enzymes, along with other 1677 
selenoproteins and selenoprotein synthesis-related Trsp, in metabolism, health, and disease. 1678 
While paradoxes associated with these enzymes signify an alternative requirement for the body 1679 
to maintain metabolic balance, harmony, and homeostasis, our understanding of the underlying 1680 
mechanisms is far from clear. We do not know how antioxidant enzymes respond to demands for 1681 
a tight control of their substrates or products in specific tissues or whole body. We know very 1682 
little of novel functions of antioxidant enzymes independent of redox modulation. Their pro-1683 
oxidant catalytic potential and mechanism are not fully recognized or understood. Likewise, little 1684 
is revealed regarding feedback mechanism of individual antioxidant enzymes and global 1685 
coordination of different enzyme families in coping with various ROS/RNS-initiated events.   1686 
 1687 
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Because most of our discussions are based on animal experiments, many of the findings need to 1688 
be verified in humans. It is clear that a number of human diseases are associated with genetic 1689 
defects or polymorphism in specific antioxidant enzymes. However, specific, sensitive, and 1690 
reliable indicators of in vivo redox status are yet explored to identify the optimal range of the 1691 
antioxidant enzyme activities and ROS/RNS tone required by individuals according to personal 1692 
genetic makeup, life style, and living environment. While mechanisms outlined in this review for 1693 
the paradoxical roles of antioxidant enzymes may lead to alternative therapy strategies, the 1694 
challenge will be to identify surfeits and deficits among the complex array of given diseases to 1695 
design the most effective treatment. Antioxidant nutrients and phytochemicals can affect 1696 
production of ROS/RNS, functions of antioxidant enzymes, and the balance between the two. It 1697 
remains to be found out when and how these supplements are beneficial, wasteful, or even 1698 
detrimental. In conclusion, antioxidant enzymes and their ROS/RNS substrates represent a pair 1699 
of natural complements. Basic mechanisms and clinical implications for their interdependence 1700 
and counterbalance in physiology and health warrant intensive research.  1701 
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FIGURE LEGENDS 1717 
 1718 
FIGURE 1.  Protective mechanisms conferred by the Sod1 knockout against APAP toxicity. The 1719 
associated mechanisms include: 1) inhibition of protein nitration; 2) up-regulation of GR and 1720 
TrxR activities; 3) down-regulation of microsomal P450 enzyme CYP2E1 activity, decreasing 1721 
NAPQI production and the subsequent GSH depletion; and 4) inhibition of cell death signaling. 1722 
Collectively, the Sod1
-/- 
mice, as shown in the bottom graph, display a 100% survival rate over 1723 
70 h, while 75% of the wild-type mice die within 20 h after an intraperitoneal injection of 600 1724 
mg APAP/kg of body weight (from reference 379). APAP, acetaminophen; Bcl-XL, B-cell 1725 
lymphoma-extra large; CYP2E1, cytochrome P450 2E1; GR, glutathione reductase; GSH, 1726 
glutathione; IκBε, inhibitor of NFκB, epsilon; JNK, c-jun N-terminal kinase; NAPQI, N-acetyl-1727 
p-benzoquinoneimine; NFκB, nuclear factor kappa-light-chain-enhancer of activated B cells; p21, 1728 
cyclin-dependent kinase interacting protein 1; PARP, poly(ADP-ribose) polymerase; and TrxR, 1729 
thioredoxin reductase.  1730 
 1731 
FIGURE 2. Protections conferred by knockouts and haploid insufficiencies of Sod1, Sod2, and 1732 
Sod3 against neural and cognitive damages induced by irradiation and brain trauma. Whereas 1733 
mechanisms for the protections against the irradiation-induced damages await further 1734 
investigation, the enhanced recovery from the brain trauma in the Sod1
-/-
 mice is associated with 1735 
attenuated H2O2 production and the subsequent NFκB activation. NFκB, nuclear factor kappa-1736 
light-chain-enhancer of activated B cells. 1737 
 1738 
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FIGURE 3. Induction or potentiation of various neurological disorders by SOD1 overexpression. 1739 
While mice overexpressing SOD1 develop signs of Down’s syndrome and muscular dystrophy, 1740 
the overexpression promotes or exacerbates pathogeneses of other listed disorders including 1741 
amyotrophic lateral sclerosis that is induced by the overexpression of mutant SOD1. Respective 1742 
biochemical and neurological mechanisms for the impacts of SOD1 overexpression, along with 1743 
their change directions (up and down arrows), are schematically shown for each of the disorders. 1744 
GSH, glutathione. 1745 
 1746 
FIGURE 4.  Aggravation of prolonged alcohol intake-induced hepatic toxicity by Sod2 1747 
overexpression. The main proposed mechanism is that Sod2 overexpression leads to 1748 
accumulation of hepatic iron that partially replaces manganese in the active site of Sod2 to form 1749 
Fe-Sod2. Consequently, Fe-Sod2 catalyzes production of hydroxyl radicals from H2O2 that cause 1750 
lipid peroxidation and mitochondrial damage. Likely, the increased hepatic iron and H2O2 may 1751 
also enhance production of hydroxyl radicals through Fenton reactions. In fact, the exacerbated 1752 
effect of Sod2 overexpression can be prevented by iron chelators. Meanwhile, the anticipated 1753 
diminished levels of superoxide anion may remove its beneficial role in limiting the propagation 1754 
of lipid peroxidation and blunt the ethanol induction of iNOS and subsequent up-regulation of 1755 
PGC-1, leading to mtDNA depletion. Fe-Sod2, iron-substituted superoxide dismutase 2; iNOS, 1756 
inducible nitric oxide synthase; mtDNA, mitochondrial DNA; NO, nitric oxide; and PGC-1, 1757 
peroxisome proliferator activated receptor gamma coactivator 1. 1758 
 1759 
FIGURE 5. Divergent effects of catalase overexpression on susceptibility to diabetes. The β-cell 1760 
specific overexpression of catalase in non-obese diabetic mice leads to early onset of 1761 
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spontaneous diabetes in male mice, with accelerated occurrence of diabetes by inhibition of the 1762 
Akt-Foxo1-Pdx1 survival pathway in islets following cyclophosphamide administration. In 1763 
contrast, such overexpression prevents diabetogenic effects of streptozotocin in non-diabetic 1764 
mice. In insulin-producing cells, finally, overexpression of catalase in mitochondria renders 1765 
strong resistances to cytokine-induced cytotoxicity, whereas its overexpression in cytoplasm 1766 
leads to weak protection. Akt, protein kinase B; Foxo1, forkhead box O1; and Pdx1, pancreatic 1767 
and duodenal homeobox 1.  1768 
 1769 
FIGURE 6. Comparative mechanisms for improved insulin sensitivity in Sod1-/- and Gpx1-/- 1770 
mice.  Knockout of Sod1 elevates hepatic IRβ protein and muscle Akt phosphorylation after 1771 
insulin stimulation, whereas knockout of Gpx1 induces only the latter. Meanwhile, embryonic 1772 
fibroblast cells from Gpx1-/- mice are manifested with enhanced Pten oxidation and PI3K/Akt 1773 
activation after insulin addition. These changes are presumably (dashed arrows) upstream of Akt 1774 
phosphorylation and result in improved insulin sensitivity. However, such impact of Sod1 1775 
deletion has not been tested yet (question mark). In addition, Gpx1-/- mice fed a high fat diet 1776 
display, following insulin challenge, enhanced glucose update through membrane docking of 1777 
glucose transporter 4 upon AS160 phosphorylation on Thr642. Akt, protein kinase B; AS160, the 1778 
160 kDa substrate of Akt; IRβ, β subunit of insulin receptor; PI3K, phosphatidylinositol-3-1779 
kinase; and Pten, phosphatase and tensin homolog. 1780 
 1781 
FIGURE 7. Distinctive mechanisms between knockouts of Sod1 and Gpx1 in lowering 1782 
pancreatic islet β cell mass and plasma insulin concentration via down-regulation of the key 1783 
transcription factor Pdx1. While knockout of Gpx1 decreases only the Pdx1 protein in islets, 1784 
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knockout of Sod1 exerts suppression at three levels of Pdx1 regulation: epigenetic, mRNA, and 1785 
protein. The down regulation of Pdx1 mRNA and protein upon Sod1 knockout coincides with 1786 
decreased mRNA and protein levels of Foxa2, a transactivator of Pdx1, as well as attenuated 1787 
binding of Foxa2, H3 acetylation, and H3K4, trimethylation in the proximal region of the Pdx1 1788 
promoter. Foxa2, forkhead box A2; H3, histone-3; K4, lysine-4; ORF, open reading frame; and 1789 
Pdx1, pancreatic and duodenal homeobox 1. 1790 
 1791 
FIGURE 8. Paradoxical roles of bovine GPX1, Gpx1 knockout, and GPX1 overexpression in 1792 
coping with PN-mediated protein nitration and toxicity in cell-free system, primary hepatocytes, 1793 
and mice. Different insult-mediated responses with net impacts of enzyme expression, and 1794 
reported or proposed mechanisms are summarized in this figure. APAP, acetaminophen; DQ, 1795 
diquat; GSH, glutathione; GST, glutathione S-transferase; PN, peroxynitrite; and SNAP, S-1796 
nitroso-N-acetyl-penicillamine.  1797 
 1798 
FIGURE 9. Mechanisms of protection conferred by Gpx1 knockout against kainic acid-induced 1799 
neurotoxicity. Gpx1 deficiency may elevate H2O2 production that can oxidize thiols in the 1800 
NMDA receptor-1 subunit, which deactivates the NMDA receptor and subsequently attenuates 1801 
or blocks kainic acid-induced oxidative stress and injuries. This oxidative stress can also be 1802 
protected by antioxidants. EUK-134, a synthetic SOD and catalase mimic; GSH, glutathione; and 1803 
NMDA, N-methyl-D-aspartate. 1804 
FIGURE 10. Molecular and biochemical mechanisms for the type 2 diabetes-like phenotypes 1805 
induced by Gpx1 overexpression in mice. The diminished H2O2 accumulation in pancreatic islets 1806 
may enhance β cell mass and insulin synthesis and secretion via modulation of key signaling 1807 
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genes and proteins at epigenetic, mRNA, and(or) protein levels. These effects lead to 1808 
hyperinsulinemia and hyper-secretion of insulin. Meanwhile, Gpx1 overexpression also impairs 1809 
insulin responsiveness in liver and muscle and disturbs lipogenesis, glycolysis, and 1810 
gluconeogenesis in those tissues. The reported modes of action for those impacts include 1811 
modulation of key gene expression, protein function, and enzyme activities. The outcomes from 1812 
these effects in insulin-responsive tissues are reflected by insulin resistance, hyperglycemia, 1813 
hyperlipidemia, and obesity. The overall phenotypes from GPx1 overexpression in either insulin 1814 
producing or insulin responsive tissues, resemble type 2 diabetes.  Representative key factors for 1815 
each of the main pathways or phenotypes are listed in brackets. Acc1, acetyl-coenzyme A 1816 
carboxylase 1; Beta2, neurogenic differentiation 1; Cat, catalase; Cfos, fbj murine osteosarcoma 1817 
viral oncogene homolog; Fasn, fatty acid synthase; Foxa2, forkhead box a2; Ins1, Insulin 1; IRβ, 1818 
the β-subunit of insulin receptor; Kir6.2, the KCNJ11 subunit of ATP-sensitive K
+
 channel; p53, 1819 
transformation related protein 53; Pdx1, pancreatic and duodenal homeobox 1; Ppar, 1820 
peroxisome proliferator-activated receptor ; Pregluc, Preproglucagon; Sur1,  sulfonylurea 1821 
receptor; Ucp2, uncoupling protein 2; Akt, protein kinase B; GK, glucokinase; PEPCK, 1822 
phosphoenolpyruvate carboxykinase; and ∆, mitochondrial membrane potential.  1823 
FIGURE 11. Intriguing roles of GPX isoenzymes in carcinogenesis. Overexpression of GPX1 in 1824 
mice promotes DMBA/TPA-induced skin cancer, whereas adenoviral delivery of GPX1 to 1825 
pancreatic tumor xenografts slows tumor growth in nude mice. This contrast illustrates tissue- or 1826 
stage-specific roles of GPX1 in carcinogenesis. As depicted in the middle yellow box, Nrf2 and 1827 
β-catenin that are associated with cancer, were shown to up-regulate GPX2 expression in 1828 
cultured human cells. Knockout of Gpx2 either stimulates or inhibits AOM-DSS-induced 1829 
intestinal tumorigenesis at early or late stages, respectively.  The relative stage-specific effects 1830 
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are indicated on the pink-colored triangle box, exemplifying the temporal dependence of the 1831 
GPX enzyme in carcinogenesis. In addition, knockout of Gpx3 in mice promotes AOM/DSS-1832 
induced colitis-associated carcinoma, but knockdown of the enzyme by shRNA inhibits leukemia 1833 
stem cell renewal. This comparison illustrates the cancer type- and(or) model-specific role of the 1834 
GPX enzyme in carcinogenesis. AOM/DSS, azoxymethane/dextran sodium sulfate; DMBA/TPA, 1835 
7,12-dimethylbenz[a]anthracene/12-O-tetradecanoylphorbol-13-acetate; Nrf2, NF-E2-related 1836 
factor 2; and shRNA, small hairpin RNA. 1837 
 1838 
FIGURE 12. Paradoxical effects of TrxR1 overexpression, genetic loss or drug inhibition. Three 1839 
separate states of TrxR1 can have either beneficial (top) or detrimental (bottom) effects in 1840 
mammals, as summarized in this figure. Native TrxR1 promotes cell viability through diverse 1841 
functions of the Trx system, including support of Prxs, Msrs, and RNR as well as modulation of 1842 
redox signaling pathways. However, cancer cells may also rely on TrxR1 activity to proliferate 1843 
and the enzyme can thus promote cancer progress as well as metastases. Genetic targeting of 1844 
TrxR1 is embryonically lethal, while conditional knockout in differentiated tissues such as 1845 
hepatocytes result in Nrf2 activation and an increased resistance to oxidative challenges. When 1846 
targeted by inhibitors, the TrxR1 enzyme can also gain an NADPH oxidase activity in addition to 1847 
loss of its native Trx1 reducing capacity, which further activates Nrf2 but can also trigger cancer 1848 
cell death, toxic side effects in normal tissues and increased dependence upon GSH for survival. 1849 
APAP, acetaminophen; Msrs, methionine sulfoxide reductases; NAPQI, N-acetyl-p-1850 
benzoquinoneimine; Nrf2, NF-E2-related factor 2; Prxs, peroxiredoxins; RNR, ribonucleotide 1851 
reductase; Trx, thioredoxin; and TrxR1, thioredoxin reductase-1. 1852 
 1853 
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FIGURE 13. Scheme of mechanisms of paradoxical outcomes upon modulation of antioxidant 1854 
enzyme status. In general, either detrimental or beneficial impacts of antioxidant enzyme 1855 
overexpression or knockout arise from complex interplays among redox active enzymes, their 1856 
substrates, and the enzymatic reaction environment. Different ROS/RNS species and antioxidant 1857 
enzymes discussed in this review are illustrated, along with their representative features (in black 1858 
text) of chemistry, free radical biology, and metabolism that may all trigger paradoxical 1859 
outcomes. Specifically, the dose, reactivity, and localization of ROS/RNS substrates can lead to 1860 
differential impacts on oxidative stress and redox signaling pathways. Impacts and mechanisms 1861 
of reductant substrates (e.g., GSH) in the “paradox” are shown in the context of antioxidant 1862 
enzyme catalysis. The antioxidant enzymes can themselves contribute to the paradoxical 1863 
outcomes by acting as pro-oxidants, either by catalyzing production of certain ROS/RNS or 1864 
over-consuming reducing equivalents, depleting ROS/RNS required for signaling, acting on non-1865 
canonical substrates, exhibiting non-redox functions, inducing compensatory responses, or 1866 
having overlapping functions with other enzymes. The environmental context, i.e. physiological 1867 
(non-stress) or pathophysiological (metabolic stress, oxidative injury, nutrient deficiency, or drug 1868 
toxicity) state, the experimental model, as well as spatial or time constraints, will determine the 1869 
final phenotype. Thus, apparent paradoxes in antioxidant enzyme overexpression and knockout 1870 
studies should be viewed in a well-defined physiological context as a combined interactions of 1871 
all of these factors. Cat, catalase, Gpx, glutathione peroxidase; Grx, glutaredoxin; MsR, 1872 
methionine sulfoxide reductase; Prx, peroxiredoxin; ROS, reactive oxygen species; RNS, 1873 
reactive nitrogen species; Sepp1, selenoprotein P; Trsp, selenocysteine tRNA gene; Sod, 1874 
superoxide dismutase; Trx, thioredoxin; and TrxR, thioredoxin reductase. 1875 
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Table 1 Commonly-used mouse models for antioxidant enzyme overexpressing and 
knockout  
Enzyme/ 
Protein 
Overexpression Knockout 
Nature of the transgene Altered site Reference Disrupted gene Altered 
site 
Reference 
Cu,Zn-
superoxide 
dismutase 
(SOD1) 
The entire human SOD1 gene 
contained in a 14.5-kb genomic 
fragment 
Brain, liver, 
heart, and lung 
(87, 170, 
681) 
Sod1 Global (264, 285, 
443, 556) 
The entire human SOD1 gene 
contained in a 64-kb genomic 
fragment 
Brain, heart, 
kidney, liver, 
lung, skeletal 
muscle, and 
spleen 
(103) 
Mn-superoxide 
dismutase 
(SOD2) 
A human SOD2 expression 
construct driven by 3.7 kb of the 
promoter and 5' flanking 
sequences of the human 
surfactant protein C gene 
Lung (703) Sod2 Global 
and 
tissue-
specific 
(291, 370, 
392, 563, 
621)  
 
A human SOD2 expression 
construct controlled by 3 kb of 5' 
flanking sequence plus 5' 
untranslated region and intron 1 
of the human β-actin gene. 
Brain, eye, 
heart, lung, 
skeletal 
muscle, 
spleen, and 
tongue 
(266, 494, 
727) 
The entire mouse Sod2 gene 
contained in a 14-kb genomic 
fragment 
Brain, heart, 
kidney, liver, 
and lung 
(542) 
A human SOD2 expression 
construct driven by 570 bp of 5’ 
flanking sequence and promoter 
of the rat insulin I gene 
Pancreatic β-
cells 
(99) 
A human SOD2 expression 
vector controlled by a 2-kb 
promoter and 10-kb enhancer of 
the mouse Tie2 (a vascular 
endothelial-specific receptor 
tyrosine kinase) gene  
Endothelial 
cells 
(226) 
A human SOD2 expression 
construct controlled by a 5.5-kb 
mouse genomic fragment 
containing the last intron of the 
β-myosin heavy chain (MHC) 
gene to exon 3 of the α-MHC 
gene 
Heart (597) 
Extracellular 
superoxide 
dismutase 
(SOD3) 
A human SOD3 expression 
construct controlled by 3 kb of 5' 
flanking sequence plus 5' 
untranslated region and intron 1 
of the human β-actin gene. 
Brain, heart, 
and skeletal 
muscle 
(509) Sod3 Global (81) 
A human SOD3 expression 
construct driven by 3.7 kb of the 
promoter and 5' flanking 
sequences of the human 
surfactant protein C gene 
Lung (189) 
Catalase A rat CAT expression construct Heart (319) Cat Global (268) 
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(CAT) downstream of a 5.5-kb mouse 
genomic fragment containing the 
last intron of the β-myosin heavy 
chain (MHC) gene to exon 3 of 
the α-MHC gene  
A human CAT expression 
construct controlled by a 2.8-kb 
mouse α-fetoprotein enhancer 
element I fused to 1.8 kb of the 
human β-globin promoter 
Liver and gut (486) 
A rat CAT expression construct 
driven by 570 bp of 5’ flanking 
sequence and promoter of the rat 
insulin I gene 
Pancreatic β-
cells 
(717) 
Three human CAT expression 
constructs (peroxisome-, 
nucleus-, and mitochondria-
targeted) driven by the  
cytomegalovirus enhancer 
element and a chicken β-actin 
promoter  
Brain, heart, 
kidney, 
skeletal 
muscle, and 
spleen 
(584, 585) 
The entire human CAT gene 
contained in a 80-kb genomic 
fragment 
Brain, heart, 
kidney, liver, 
lung, skeletal 
muscle, and 
spleen 
(103) 
Glutathione 
peroxidase 1 
(GPX1) 
A human GPX1 expression 
construct controlled by the 
promoter, exon 1, and intron 1 of 
the mouse 
hydroxymethylglutaryl-
coenzyme A reductase gene  
Brain, heart, 
kidney, and 
liver 
(457) Gpx1 Global (141, 172, 
265) 
A human GPX1 expression 
construct controlled by rat 
insulin II promoter 
Pancreas (244) 
The entire mouse Gpx1 gene 
contained in a 5.3-kb genomic 
fragment 
Brain, eye, 
heart, lung, 
skeletal 
muscle, 
spleen, 
pancreas, and 
tongue 
(109, 716, 
733)  
Gastrointestinal 
glutathione 
peroxidase 
(GPX2) 
   Gpx2 Global (176, 186) 
Glutathione 
peroxidase 3 
(GPX3) 
 A human GPX3 expression 
construct controlled by the 
promoter, exon 1, and intron 1 of 
the mouse 
hydroxymethylglutaryl-
coenzyme A reductase gene 
Kidney, brain, 
and lung 
 
(457) Gpx3 Global (311) 
Phospholipid 
hydroperoxide 
glutathione 
A rat mitochondria-targeted 
Gpx4 expression driven by the 
human cytomegalovirus 
Mitochondria 
of the heart 
(136) Gpx4 Global, 
neurons, 
spermatoc
(52, 292, 
293, 581, 
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peroxidase 
(GPX4) 
immediate early enhancer and 
chicken β-actin promoter 
ytes, 
cytosol, 
mitochon
dria, 
nucleus  
590, 725) 
 A 50-kb genomic clone 
containing the entire human 
GPX4 gene  
Cerebral 
cortex, heart, 
skeletal 
muscle, 
kidney, liver 
and testes 
(548) 
Peroxiredoxin I 
(PRX1) 
   Prx1 Global (338, 484) 
Peroxiredoxin 
II (PRX2) 
   Prx2 Global (375) 
Peroxiredoxin 
III (PRX3) 
A rat Prx3 expression construct 
driven by the cytomegalovirus 
promoter  
Mitochondria 
of the heart 
(440) Prx3 Global (389) 
Peroxiredoxin 
IV (PRX4) 
A human PRX4 expression 
construct driven by the enhancer 
and promoter of the human 
cytomegalovirus immediate 
early gene  
Brain, heart, 
kidney, 
pancreas, and 
testis 
(155) Prx4 Global (300) 
Peroxiredoxin 
VI (PRX6) 
A 16.8-kb genomic fragment 
containing the entire mouse Prx6 
gene isolated from 129SvJ mice 
Intestine, 
kidney, liver, 
lung, and 
epithelial cells 
of all tissues 
(531) Prx6 Global (461, 683) 
Thioredoxin 1 
(TXN1 or 
TRX1) 
A human TXN1 expression 
construct controlled by the 
human insulin promoter and 
exons and introns of the rabbit β 
globin gene 
Pancreas (281) Txn1/Trx1 Global (438) 
A human TXN1 expression 
construct driven by 3 kb of 5' 
flanking sequence plus 5' 
untranslated region and intron 1 
of the human β-actin gene. 
Brain, heart, 
kidney, liver, 
lung, , skeletal 
muscle, 
spleen, and 
tongue 
(3, 661) 
The structure of the human 
TXN1 transgene is not 
described. 
Brain, heart, 
kidney, liver, 
lung, and skin 
(636)    
Thioredoxin 2 
(TXN2 or 
TRX2) 
The structure of the human 
TXN2 transgene is not described  
Heart (696) Txn2/Trx2 Global (490) 
Thioredoxin 
reductase 1 
(TrxR1) 
   Txnrd1 Global, 
neurons, 
liver, 
heart 
(79, 305) 
Thioredoxin 
reductase 2 
(TrxR2) 
   Txnrd2 Global, 
neurons, 
heart 
(123, 330) 
Selenoprotein P 
(SEPP1)  
   Sepp1  Global  (259, 583) 
Glutaredoxin 1 
(Grx1or Glrx1 
  (478) Glrx1 global (4, 267, 
270)  
Glutaredoxin 2 
(Grx2 or Glrx2) 
   Grx2 global (426, 427, 
710) 
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Selenocysteine 
tRNA (Trsp) 
A 1.93-kb genomic DNA 
containing the entire mouse Trsp 
gene with mutations of TC at 
position 9 and AG at position 
37 
Brain, kidney, 
liver, and 
testes 
(471) Trsp Global 
and 12 
tissue-
specific 
knocko
ut 
(54, 356) 
Methionine 
sulfoxide 
reductase A 
(MSRA) 
Three mouse MsrA expression 
constructs (wild-type, 
mitochondria-targeted, and 
cytosolic) controlled by the 
cytomegalovirus enhancer and 
chicken β-actin promoter. 
Liver, skin 
fibroblasts 
(752) MsrA Global (468) 
Methionine 
sulfoxide 
reductase B 
(MSRB) 
   MsrB1 Global (190) 
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Table 2. Physiological impacts or pathological responses of superoxide dismutase-1 
overexpression and knockout in mice 
  
Organ/ 
Condition 
Phenotype Reference 
 
O
v
er
ex
p
re
ss
io
n
 
Brain and 
neurological 
system 
 
Ameliorate brain injuries induced by cold or subarachnoid hemorrhage (in rats) via 
suppressing MMP-2 and MMP-9 or activation of Akt/GSK-3β.  
(93, 169, 313, 
467) 
Protect vulnerable motor neurons after spinal cord injury via attenuating the 
mitochondrial apoptosis pathway (in rats) 
(624, 737) 
Attenuate kainic acid-induced neurotoxicity in hippocampus and striatum   (260, 586) 
Alleviate phenotypes of Parkinson’s disease by elevating dopamine and suppressing 
lipid peroxidation, protein nitration  
(294, 536, 
647) 
Vascular 
system 
Protect against post-angioplasty response and neointimal formation (adenovirus-
mediated gene overexpression in rabbit tissue) 
(358) 
Lung 
Alleviate pulmonary oxygen toxicity and prolong survival    (695) 
Resistant to allergen-induced changes in airway control  (369) 
Ischemic 
injury 
Protect against cerebral ischemic injury (in mice/rats) 
(100, 345, 
476) 
Render the heart resistant to myocardial ischemia/reperfusion injuries and protect 
against ischemia-reperfusion injury, inflammatory responses and apoptosis in cardiac 
graft 
(106, 642, 
681) 
Diabetes 
Protect against diabetogenesis and diabetic nephropathy by suppressing glomerular 
nitrotyrosine formation and matrix protein synthesis  
(129, 148, 
354) 
Abolish maternal diabetes-induced embryopathy, block maternal hyperglycemia-
induced activation of PKCα/βII and PKCδ and lipid peroxidation  
(232, 391, 
679) 
Cancer Reduce mutation frequency in cerebellum (357) 
K
n
o
ck
o
u
t 
Brain and 
neurological 
system 
 
Undergo marked hypertrophy and altered responses to acetylcholine in cerebral 
arterioles  
(36, 152) 
Vulnerable to axonal injury such as axotomy and ischemic insults, and altered calcium 
homeostasis in spinal motor neurons   
(556, 611) 
Increase susceptibility to MPTP-induced phenotypes of Parkinson’s disease    (746) 
Drive phenotypes of Alzheimer’s disease such as Aβ oligomerization and memory 
loss  
(477) 
Display a modified distribution of fiber types and fiber loss, muscle atrophy and 
weakness  
(348, 349, 
367) 
Vascular 
system 
Lead to dysfunctions in endothelial-dependent vasodilation and myogenic tone, and 
accelerated vascular aging in endothelial progenitor cells  
(125, 151, 152, 
228, 674) 
Lung 
Increase NFAT activity and NFATc3 nuclear localization resulted from elevated 
superoxide/H2O2 ratio,  induce spontaneous pulmonary hypertension in pulmonary 
arteries 
(546) 
Liver 
Alter hepatic gluconeogenesis, glycolysis, and lipogenesis, and induce lipid 
accumulation by impaired lipoprotein secretion 
(662, 680) 
Enhance sensitivity to acute paraquat and alcohol-induced liver toxicity  (264, 329) 
Ischemic 
injury 
Impair neovascularization induced by hindlimb ischemia  (228) 
Aggravate ischemia/reperfusion-induced myocardial, hippocampal and renal injuries 
(in mice/rats) 
(100, 719, 
731) 
Diabetes 
Accelerate diabetic renal injury  (147) 
Impair islet function, pancreas integrity, and body glucose homeostasis by elevating 
islet superoxide, upregulating p53 phosphorylation and downregulating Foxa2/Pdx1 
pathway 
(684) 
Increase susceptibility to ocular disorders such as cataract and progressive retinal cell 
loss  
(247, 295, 
500-503) 
Immune 
response 
Increase susceptibility to the experimental autoimmune encephalomyelitis  (436) 
cause anemia and autoantibody production by elevating oxidative stress in 
erythrocytes 
(299) 
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Kidney 
Exhibit an increase in phosphorylation of iron regulatory protein 1(IRP1) in kidney, 
leading to increased binding to iron-responsive elements (IREs)  
(734) 
Susceptible to hydronephrosis- and salt-induced hypertension and histopathological 
changes  
(82) 
Cancer 
Show reduced lifespan and increased carcinogenesis in late life with oxidative 
damage-accelerated spontaneous mutations in liver and kidney  
(73, 167) 
Others 
Lead to embryonic two-cell arrest or cell death, and impaired sperm motility and 
fertilizing ability 
(207, 334, 
658) 
Induce age-related dysfunction of the lacrimal gland, potentiate hearing loss, cochlear 
pathology, bone stiffness/strength, skin morphology and wound healing 
(301, 346, 
446, 614) 
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Table 3. Physiological impacts and pathological responses of superoxide dismutase-2 
overexpression and knockout in mice 
  
 Organ/ 
Condition 
  Phenotype Reference 
O
v
er
ex
p
re
ss
io
n
 
Brain and 
neurological 
system 
Attenuate MPTP-induced phenotypes of Parkinson’s disease (342) 
Attenuate phenotypes of Alzheimer’s disease by reducing hippocampal oxidative 
stress, modulating Aβ deposition and composition,  and slowing memory deficit  
(164, 435) 
Lung 
Prevent hypoxia-mediated decrease in Na,K-ATPase and alveolar fluid reabsorption 
(adenovirus-mediated gene overexpression in rats)   
(401) 
Liver 
Protect against liver mitochondrial DNA depletion and respiratory complex 
dysfunction after an alcohol binge  
(433) 
Diabetes 
Ameliorate high-fat diet-induced insulin resistance in rat skeletal muscle 
(electroporation delivery of expression vector to rat muscle ) 
(50) 
Prevent retinal VEGF expression and retinopathy in diabetic mice  (226, 351) 
Normalize contractility in diabetic cardiomyocytes with improved mitochondrial 
respiration  
(597) 
Ischemic injury 
Reduce  ischemia/reperfusion-induced vascular endothelial cell death and protects 
against blood-brain barrier damage 
(425) 
Reduces neuronal vulnerability to forebrain ischemia (injection of astrocyte-specific 
expression vector to rat brain) 
(718) 
Protect against myocardial ischemia/reperfusion-induced injury (107) 
Aging 
Preserve age-associated loss of mitochondrial DNA mass and function of ATP 
generation 
(308, 374) 
K
n
o
ck
o
u
t 
Brain and 
neurological 
system 
Show selective cerebral vascular dysfunction and accelerated disorganization of 
distal nerve axons following nerve injury 
(179, 459) 
Exacerbate phenotypes of Alzheimer disease, Parkinson’s disease and ALS  (11, 12, 
385) 
Exhibit  neurodegenerative phenotypes including frequent, spontaneous motor 
seizures 
(188, 394) 
Liver  
Exaggerate APAP-induced liver toxicity, mitochondrial dysfunction and DNA 
fragmentation 
(200, 545) 
Diabetes 
Result in severe central nervous system degeneration and subsequent gait 
deformities, seizures, and perinatal lethality in type 2 diabetes  
(497) 
Heart  
Induce cardiac mitochondrial dysfunction, severe lipid peroxidation and spontaneous 
apoptosis in myocardium, and maladaptive cardiac hypertrophy  
(563, 621, 
671) 
Vascular system 
Lead to increased vascular oxidative stress with aging and endothelial dysfunction in 
large and mesenteric arteries   
(65, 138, 
498, 720) 
Up-regulate transferrin receptor and down-regulate mitochondrial biogenesis and 
metabolism in erythroid cells  
(434) 
Kidney  Develop hypertension, mild renal damage and interstitial inflammation in aged mice  (516, 567) 
Cancer Elevate incidence of neoplasms in aging Sod2+/-Gpx1-/- mice (750) 
Ischemic injury 
Increased susceptibility to cerebral ischemia/reperfusion with activation of MMPs, 
inflammation, blood-brain barrier breakdown and high brain hemorrhage rates 
(425) 
Aging Lead to reduced lifespan and premature onset of aging-related phenotypes  (653, 675) 
Others 
Reduce contractile muscle function and aerobic exercise capacity during aging   (335, 417, 
418) 
Ocular pathology including progressive retinal thinning (578) 
A significant decrease in the respiratory capability and an increased rate of induction 
of the permeability transition in mitochondria 
(697) 
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Table 4. Physiological impacts and pathological responses of superoxide dismutase-3 
overexpression and knockout in mice 
  
 Organ/ 
Condition 
Phenotype Reference 
O
v
er
ex
p
re
ss
io
n
 
Brain and 
neurological 
system   
Protect against brain injury induced by subarachnoid hemorrhage, hyperoxia or cold 
(447, 510, 
739) 
Improve behavioral outcome from closed head injury (532) 
Protect against aging-induced memory and cognitive impairments (381, 382) 
Vascular 
system 
Reduce cuff-induced arterial neointimal formation (adenovirus-mediated gene 
expression in rat tissue) 
(511) 
Lung  
Attenuate pulmonary oxygen toxicity  by increasing cGMP activity and reducing of 
NFκB activation (aerosolized delivery of expression plasmid to neonatal rabbits) or 
by attenuating neutrophil inflammatory responses 
(7, 189) 
Preserve pulmonary angiogenesis by retaining VEGF,  VEGFR1, VEGFR2 and 
PECAM-1 
(528) 
Inhibit the development of hypoxia- or fibrosis-induced pulmonary hypertension and 
vascular remodeling, and ameliorate established pulmonary hypertension 
(8, 492, 672) 
Attenuate radiation-, endotoxin (adenovirus-mediated expression)-, influenza- or air 
pollutant-induced lung injury 
(212, 248, 
318, 539, 625) 
Immune 
response 
Attenuate inflammatory arthritis by suppressing the production of proinflammatory 
cytokines and MMPs 
(736) 
Ischemic injury 
Increased resistance to heart or cerebral ischemia/reperfusion injuries 
(97, 98, 493, 
598, 600) 
Improve recovery from surgical hind-limb ischemia (adenovirus-mediated gene 
expression) 
(579) 
Cancer Inhibit chemical-induced skin carcinogenesis (332)  
K
n
o
ck
o
u
t 
Heart  Exacerbate pressure overload-induced left ventricular hypertrophy and dysfunction (414) 
Lung  Increased susceptibility to hyperoxia (81) 
Kidney  
Exhibit renal histopathological abnormalities, hypertension, endothelial dysfunction, 
and reduced eNOS and Akt activity 
(326) 
Immune 
response 
Increased susceptibility to the collagen-induced arthritis 
(570) 
Ischemic injury Worsen the outcome from cerebral or skeletal muscle ischemia/reperfusion (519, 599) 
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Table 5. Physiological impacts and pathological responses of catalase overexpression and 
knockout in mice 
  
 Organ/ 
Condition 
Phenotype Reference 
O
v
er
ex
p
re
ss
io
n
 
Heart  
Preserve the responsiveness of the heart to adrenergic stimulation  (704) 
Attenuate cardiac contractile dysfunction induced by paraquat, anthrax, LPS, acute 
ethanol, or  hypoxia-reoxygenation, through alleviating events such as JNK-mediated 
ER stress 
(105, 208, 
317, 660, 
748, 749) 
Prevent progressive myocardial remodeling, including myocyte hypertrophy, apoptosis, 
and interstitial fibrosis due to overexpression of  Gαq 
(538) 
Protect against acute and chronic doxorubicin-induced cardiotoxicity (319, 320) 
Vascular 
system 
Prevent pathological mechanical changes underlying abdominal aortic aneurysm 
formation  
(424) 
Reduce pressure response to norepinephrine or angiotensin II  by eliminating H2O2 in 
arterial wall  
(723) 
Inhibit toxin-accelerated atherosclerosis in the hypercholesterolemic ApoE-/- mice  (722, 724) 
Kidney  
Inhibit the development of hypertension and renal injury in the angiotensinogen 
transgenic mice 
(219) 
Ischemic injury Render the heart resistant to myocardial ischemia/reperfusion injury  (386) 
Diabetes 
Increase resistance to STZ-induced β-cell injury and diabetic effect including an 
attenuation of  renal angiotensinogen and proapoptotic gene expression 
(58, 99, 
717) 
Cardiac overexpression rescues insulin resistance-induced cardiac contractile 
dysfunction  
(160) 
Prevent hypertension and progression of nephropathy by attenuating renal oxidative 
stress and normalizing ACE-2 expression in type 1 diabetes 
(603) 
Aging 
Mitochondrial overexpression prolongs lifespan with delayed age-associated 
pathologies including cardiac aging and cataract, decreases malignant 
nonhematopoietic tumor burden in old mice and  enhances hippocampus-dependent 
memory with a reduction of anxiety   
(137, 504, 
584, 654) 
Cardiac overexpression prolongs lifespan and attenuates aging-induced cardiomyocyte 
contractile dysfunction and protein carbonyl formation  
(712) 
K
n
o
ck
o
u
t Brain  
Show a decreased efficiency in brain mitochondrial respiration following cortical 
oxidative injury 
(268) 
Kidney  
Render remnant kidneys increased susceptibility to oxidant tissue injury and 
progressive renal fibrosis after nephrectomy 
(344) 
Diabetes 
Accelerate STZ-induced diabetic renal injury with increased expression of glomerular 
TGF-β and collagen α1 
(289) 
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Table 6. Physiological impacts and pathological responses of glutathione peroxidase-1 
overexpression and knockout in mice 
  
  Organ/ 
Condition 
Phenotype Reference 
 
O
v
er
ex
p
re
ss
io
n
 
Brain and 
neurological system 
Protect against 6-OHDA-induced neurotoxicity, trauma-induced 
mitochondrial dysfunction, cerebral/ischemia reperfusion and  hypoxic 
ischemic injury 
(42, 564, 595, 
691, 716) 
Heart 
Resistant to ischemia/reperfusion injury and doxorubicin-induced 
cardiomyopathy and mitochondrial dysfunction 
(714, 733) 
Liver 
Protect against paraquat-induced hepatotoxicity  (111) 
Enhanced susceptibility to acetaminophen toxicity  (458) 
Diabetes and 
metabolic 
disorders 
Contribute to hyperinsulinemia in association with the transcription 
factor PDX1 and mitochondrial uncoupling protein 2  
(686) 
β-cell-specific overexpression of human GPX1 rescues β-cell 
dysfunction and reverses diabetes in 20-week-old db/db obesity mice 
(229, 244) 
Gpx1 overexpression mice are obese  (445) 
K
n
o
ck
o
u
t 
Brain and 
neurological system 
Exacerbate neuronal toxicity induced by Aβ,  malonate, 3-nitropropionic 
acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine 
(128, 341) 
Resistant to kainic acid-induced seizure and neurodegeneration  (309) 
Heart 
Susceptible to ischemia/reperfusion injury in male mice (397, 732) 
Mutate the benign coxsackievirus B3 and induce myocarditis  (37) 
Susceptible to doxorubicin- and angiotensin II-induced aortic and cardiac 
dysfunction and oxidative stress  
(15, 206) 
Accelerated progression of atherosclerosis under a diabetic ApoE-/- 
background on a high fat diet (21% fat, 0.15% cholesterol)  
(384, 652) 
Liver and kidney 
 
Enhanced susceptibility to diquat- and paraquat-induced oxidative stress  (110, 112, 
114, 199) 
Resistance to peroxynitrite-mediated hepatic toxicity  (199) 
Accelerated diabetic nephropathy in the ApoE-/- model of diabetes  (115, 640, 
641) 
Lung  
Enhanced oxidation and lung inflammation after cigarette smoking or 
influenza A infection  
(165, 726) 
Aging  No apparent phenotype except for cataract  (142, 265) 
Carcinogenesis 
Gpx1-/-Gpx2-/- mice have spontaneous polyps formation and 
inflammation-induced tumor formation in the gastrointestinal tract  
(174) 
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Table 7. Physiological impacts and pathological responses of glutathione peroxidases 2-4 
overexpression and knockout in mice 
  
  Organ/ 
Condition 
Phenotype Reference 
 
O
v
er
 
ex
p
re
ss
i
o
n
 
Heart Mitochondrial Gpx4 (rat) attenuates ischemia/reperfusion cardiac injury  (136) 
Liver  
Human GPX4 protects against diquat-induced apoptosis and oxidative stress  (393, 548) 
Increased expression of human GPX3 in the plasma by 50% renders the mice 
resistant to APAP-induced hepatotoxicity and a thermosensitive phenotype 
(457, 458) 
K
n
o
ck
o
u
t 
Brain  and 
neurological 
system 
Gpx3-/-:  display cerebral infarctions  (311) 
Gpx4+/-:  accumulate oxidized lipids and senile plagues  (101) 
Mitochondrial Gpx4-/- : apoptosis-induced cerebral degeneration in the hindbrain  (52) 
Gpx4-/- (neuron-specific): neurodegeneration, corrected by α-tocopherol (590) 
Gpx4-/- (endothelium-specific):  vitamin E-dependent suppression of 
angiogenesis in aortic explants  
(707) 
Nuclear  Gpx4-/-: retardation in atrium formation  (52) 
Carcinogenesis 
Gpx2-/-: severe inflammation and colon carcinoma induced by AOM/DSS; 
prone to UV-induced squamous cell tumor  
(352, 678) 
Gpx3-/-:   prone to colitis-associated carcinoma and increased inflammation in 
the colon  
(32) 
Aging Gpx4+/-:  a slight lifespan extension (1029 vs 963 days)  (549) 
Others 
Gpx4-/- (photoreceptor-specific): degeneration and apoptotic death of 
photoreceptor cells  
(663) 
Gpx4-/- (spermatocytes-specific): infertility; reduced forward mobility and 
mitochondrial membrane potential in the  spermatozoa 
(292) 
Mitochondrial Gpx4-/- : infertility; impaired sperm quality and severe structural 
abnormalities in the midpiece of spermatozoa  
(581) 
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Table 8. Physiological impacts and pathological responses of thioredoxin reductases 
knockout in mice 
Gene/Isoenzyme/
Deletion 
Organ 
(Genetic model) 
Phenotype Reference 
Txnrd1 (TrxR1, 
TR1) 
   
K
n
o
ck
o
u
t 
Ubiquitous deletion Early embryonic lethality  (51, 305) 
Heart 
(MLC2a-driven knockout) 
No apparent phenotype and no effect on infarct 
size after cardiac ischemic/reperfusion injury  
(280, 305) 
Nervous system (Nestin-
driven knockout) 
Smaller mice with ataxia and tremor, cerebellar 
hypoplasia, ectopically located and abnormal 
Purkinje cells, disorganized Bergmann glial 
network. 
(617) 
Neurons 
(Tα1-driven knockout) 
No apparent phenotype (617) 
Liver 
(Alb-driven knockout) 
Strong upregulation of Nrf2-targeted genes, no 
apparent growth defect in non-treated liver but 
metabolic switch with accumulation of 
glycogen or lipids and significantly increased 
resistance to acetaminophen challenge 
(302, 520, 
535, 634) 
B-cell lymphoma 
(mb-1-driven knockout in 
λ-myc lymphoma model) 
No effect on tumor growth except induction of 
an absolute requirement of the tumors on GSH 
upon Txnrd1 knockout 
(430) 
Hepatocellular carcinoma 
(induced by 
diethylnitrosamine in Alb-
driven knockout) 
Strongly increased propensity for 
hepatocarcinogenesis  
(79) 
Txnrd2 (TrxR2, 
TR2) 
   
K
n
o
ck
o
u
t 
Ubiquitous 
Early embryonic lethality with impaired heart 
development, anemia, lack of hematopoiesis 
and liver apoptosis 
(123) 
Nervous system (Nestin-
driven knockout) 
No apparent phenotype (617) 
Heart 
(MLC2a-driven knockout) 
Congestive heart failure with signs of dilated 
cardiomyopathy, death within hours after birth 
(123) 
Heart 
(tamoxifen-induced α-
myosin heavy chain-driven 
knockout) 
Impaired cardiac function at rest and more 
severe injuries after cardiac 
ischemia/reperfusion, with NAC treatment 
normalizing the observed phenotypes 
(280) 
B- and T-cells (CD4- and 
CD19-driven knockouts) 
No apparent phenotype (209) 
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 Table 9. Physiological impacts and pathological responses of overexpression, knockout, 
and transgene of other selenium-dependent proteins and Trsp in mice 
 
 Models Phenotypes Reference 
T
rs
p
 t
ra
n
sg
en
e 
Lacking the STAF-
binding site 
Tissue-specific decrease in selenoprotein expression (brain, muscle > 
lung, spleen > liver, kidney; no change in heart and testes) 
(77) 
Mutation at position 
37 (A G) 
Tissue- and selenoprotein-specific changes in selenoprotein expression 
(GPX1, TrxR1, liver > testes); pyogranulomatous inflammation in 
various tissues   
(470, 471) 
mTOR-dependent increase of muscle growth after exercise  (279) 
Severe neurological defects and mortality in these mice on a Se-deficient 
or high Se (2.25 ppm) diet 
(324) 
Increased susceptibility to azoxymethane-,  diethylnitrosamine-, and  
C3(1)-induced carcinogenesis in intestines, liver, and prostate, 
respectively; no changes on TGFα-induced hepatocarcinogenesis  
(159, 296, 
324, 470) 
Increased X-ray-induced micronuclei formation in the erythrocytes  (27) 
Defective immune responses after the lungs were targeted with viral 
infection of influenza 
(601) 
T
rs
p
 c
o
n
d
it
io
n
a
l 
k
n
o
ck
o
u
t 
Hematopoietic cells 
(Mx1-driven) 
Prone to hemolytic anemia and defective oxidative homeostasis  (327) 
Macrophage 
(LysM-driven) 
Increased oxidative stress, induction of Nrf2 expression, defective 
immune response and expression of fibrosis-associated genes 
(635)  
T cells 
(Lck-driven) 
Defective T cell maturation and antibody responses upon T cell receptor 
stimulation 
(608) 
Neuron 
(T1-driven) 
Defects in interneuron development and cerebellar hypoplasia, increased 
striatal neuronal loss with movement disorder, and seizure due to 
spontaneous epileptiform activity 
(588, 701, 
702) 
Endothelial cells 
(TieTeK2-driven) 
Embryonic lethal. 14.5 days embryos are smaller with underdeveloped 
vascular system, limbs, tail and head  
(609) 
Osteo-
chondroprogenitor 
(Col2a1-driven) 
Growth retardation and delayed skeletal ossification reminiscent of 
Kashin-Beck disease 
(161) 
Skin 
(K14-driven) 
Small body size, alopecia, flaky and fragile skin, and early regression of 
hair follicles 
(592) 
Heart and skeletal 
muscle (MCK-driven) 
Die 12 days after birth with acute myocardial failure (609) 
Mammary gland (MMTV- 
or Wap-driven) 
Increased mammary carcinogenesis (288) 
Liver (Alb-driven) 
Premature death at 1-3 months of age, no changes in brain Se levels, and 
increased apolipoprotein E and cholesterol levels in plasma 
(76, 587, 
591) 
Kidney (NPHS2-driven) No effect on streptozotocin-induced diabetes (48) 
Prostate epithelium 
(ARR2PB-driven) 
Early onset of intraepithelial neoplasia (415) 
T
rs
p
 
k
n
o
ck
o
u
t 
 
a
n
d
 
tr
a
n
sg
en
e Mutant G37 transgene 
under global Trsp-/- 
Reduced fertility in males and litter size in females  (78) 
A34 or G37 
transgene in liver-
specific Trsp-/- 
Reversal of the elevated levels of apolipoprotein E and cholesterol in the 
plasma  
(591) 
 
Sepp1-/- 
Neuronal degeneration, loss of 55% Se in the brain, degenerated and 
dystrophic axons in the cervical spinal cords and the brainstem 
(259, 533, 
583) 
Sepp1∆240-361 Decreased Se levels in the brain (258) 
MsrB1-/- 
Oxidation of protein, lipid, and GSH in liver and kidney; actin 
fragmentation 
(190, 371) 
100 
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